Interleukin-6	B-protein
promotes	O
multiple	O
myeloma	O
cell	O
growth	O
via	O
phosphorylation	O
of	O
retinoblastoma	B-protein
protein	I-protein
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
(	I-cell_line
MM	I-cell_line
)	I-cell_line
cells	I-cell_line
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

Abnormalities	O
of	O
retinoblastoma	B-protein
protein	I-protein
(	O
pRB	B-protein
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Because	O
dephosphorylated	B-protein
(	I-protein
activated	I-protein
)	I-protein
pRB	I-protein
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	B-protein
(	I-protein
inactivated	I-protein
)	I-protein
pRB	I-protein
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	B-protein
in	O
IL-6	B-protein
-mediated	O
MM	O
cell	O
growth	O
.	O

Both	O
phosphorylated	O
and	O
dephosphorylated	O
pRB	B-protein
were	O
expressed	O
in	O
all	O
serum-starved	O
MM	O
patient	O
cells	O
and	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
pRB	B-protein
was	O
predominantly	O
in	O
its	O
phosphorylated	O
form	O
.	O

In	O
MM	B-cell_line
cells	I-cell_line
that	O
proliferated	O
in	O
response	O
to	O
IL-6	B-protein
,	O
exogenous	O
IL-6	B-protein
downregulated	O
dephosphorylated	B-protein
pRB	I-protein
and	O
decreased	O
dephosphorylated	O
pRB-E2F	B-protein
complexes	I-protein
.	O

Importantly	O
,	O
culture	O
of	O
MM	B-cell_line
cells	I-cell_line
with	O
RB	O
antisense	O
,	O
but	O
not	O
RB	O
sense	O
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	B-protein
secretion	O
and	O
proliferation	O
in	O
MM	B-cell_line
cells	I-cell_line
;	O
however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti-IL-6	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
MoAb	B-protein
)	O
.	O

In	O
contrast	O
to	O
MM	B-cell_line
cells	I-cell_line
,	O
normal	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
express	O
dephosphorylated	B-protein
pRB	I-protein
.	O

Although	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	B-protein
and	O
proliferation	O
of	O
B	B-cell_type
cells	I-cell_type
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	B-protein
to	O
CD40L	B-protein
-treated	O
B	B-cell_type
cells	I-cell_type
does	O
not	O
alter	O
either	O
pRB	B-protein
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	B-protein
pRB	I-protein
is	O
constitutively	O
expressed	O
in	O
MM	B-cell_line
cells	I-cell_line
and	O
that	O
IL-6	B-protein
further	O
shifts	O
pRB	B-protein
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	B-protein
pRB	I-protein
due	O
to	O
reduced	O
dephosphorylated	B-protein
pRB	I-protein
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	B-protein
secretion	O
by	O
MM	B-cell_line
cells	I-cell_line
and	O
related	O
IL-6	B-protein
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Interleukin-6	NULL
Promotes	NULL
Multiple	NULL
Myeloma	NULL
Cell	NULL
Growth	NULL
Via	NULL
Phosphorylation	NULL
of	NULL
Retinoblastoma	NULL
Protein	NULL
By	NULL
Mitsuyoshi	NULL
Urashima	NULL
,	NULL
Atsushi	NULL
Ogata	NULL
,	NULL
Dharminder	NULL
Chauhan	NULL
,	NULL
Maria	NULL
B.	NULL
Vidriales	NULL
,	NULL
Gerrard	NULL
Teoh	NULL
,	NULL
Yasutaka	NULL
Hoshi	NULL
,	NULL
Robert	NULL
L.	NULL
Schlossman	NULL
,	NULL
James	NULL
A.	NULL
DeCaprio	NULL
,	NULL
and	NULL
Kenneth	NULL
C.	NULL
Anderson	NULL
interleukin-6	NULL
(	NULL
IL-6	NULL
)	NULL
mediates	NULL
autocrine	NULL
and	NULL
paracrine	NULL
growth	NULL
of	NULL
multiple	NULL
myeloma	NULL
(	NULL
MM	NULL
)	NULL
cells	NULL
and	NULL
inhibits	NULL
tumor	NULL
cell	NULL
apoptosis	NULL
.	NULL

Abnormalities	NULL
of	NULL
retinoblastoma	NULL
protein	NULL
(	NULL
pRB	NULL
)	NULL
and	NULL
mutations	NULL
of	NULL
RB	NULL
gene	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
up	NULL
to	NULL
70	NULL
%	NULL
of	NULL
MM	NULL
patients	NULL
and	NULL
80	NULL
%	NULL
of	NULL
MM-derived	NULL
cell	NULL
lines	NULL
.	NULL

Because	NULL
dephosphorylated	NULL
(	NULL
activated	NULL
)	NULL
pRB	NULL
blocks	NULL
transition	NULL
from	NULL
G1	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
whereas	NULL
phosphorylated	NULL
(	NULL
inactivated	NULL
)	NULL
pRB	NULL
releases	NULL
this	NULL
growth	NULL
arrest	NULL
,	NULL
we	NULL
characterized	NULL
the	NULL
role	NULL
of	NULL
pRB	NULL
in	NULL
IL-6-mediated	NULL
MM	NULL
cell	NULL
growth	NULL
.	NULL

Both	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
were	NULL
expressed	NULL
in	NULL
all	NULL
serum-starved	NULL
MM	NULL
patient	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
but	NULL
pRB	NULL
was	NULL
predominantly	NULL
in	NULL
its	NULL
phosphorylated	NULL
form	NULL
.	NULL

In	NULL
MM	NULL
cells	NULL
that	NULL
proliferated	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
,	NULL
exogenous	NULL
IL-6	NULL
downregulated	NULL
dephosphorylated	NULL
pRB	NULL
and	NULL
decreased	NULL
dephosphorylated	NULL
pRB-E2F	NULL
complexes	NULL
.	NULL

Importantly	NULL
,	NULL
culture	NULL
of	NULL
MM	NULL
cells	NULL
with	NULL
RB	NULL
antisense	NULL
,	NULL
but	NULL
not	NULL
RB	NULL
sense	NULL
,	NULL
oligonucleotide	NULL
(	NULL
ODN	NULL
)	NULL
triggered	NULL
IL-6	NULL
secretion	NULL
and	NULL
proliferation	NULL
in	NULL
MM	NULL
NTERLEUKIN-6	NULL
(	NULL
IL-6	NULL
)	NULL
is	NULL
a	NULL
cytokine	NULL
with	NULL
pleiotropic	NULL
activities	NULL
,	NULL
including	NULL
induction	NULL
of	NULL
differentiation	NULL
and	NULL
regulation	NULL
of	NULL
growth	NULL
in	NULL
a	NULL
cell	NULL
type	NULL
dependent	NULL
manner	NULL
.	NULL
``	NULL

It	NULL
was	NULL
originally	NULL
described	NULL
as	NULL
a	NULL
factor	NULL
that	NULL
promoted	NULL
differentiation	NULL
of	NULL
normal	NULL
B	NULL
cells	NULL
to	NULL
antibody	NULL
(	NULL
Ab	NULL
)	NULL
producing	NULL
cells	NULL
,	NULL
without	NULL
triggering	NULL
B-cell	NULL
proliferation	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
IL-6	NULL
is	NULL
known	NULL
to	NULL
be	NULL
a	NULL
growth	NULL
factor	NULL
both	NULL
for	NULL
human	NULL
multiple	NULL
myeloma	NULL
(	NULL
MM	NULL
)	NULL
and	NULL
mouse	NULL
plasmacytoma	NULL
cells	NULL
.	NULL

Specifically	NULL
,	NULL
multiple	NULL
reports	NULL
support	NULL
an	NULL
autocrine	NULL
IL-6-mediated	NULL
growth	NULL
mechanism	NULL
in	NULL
MM	NULL
,	NULL
as	NULL
some	NULL
MM	NULL
cells	NULL
and	NULL
derived	NULL
cell	NULL
lines	NULL
both	NULL
produce	NULL
and	NULL
respond	NULL
to	NULL
IL-6	NULL
in	NULL
vitro	NULL
.	NULL

*	NULL
``	NULL
``	NULL
An	NULL
IL-6-mediated	NULL
paracrine	NULL
growth	NULL
mechanism	NULL
has	NULL
also	NULL
been	NULL
postulated	NULL
,	NULL
based	NULL
on	NULL
these	NULL
observations	NULL
:	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
(	NULL
BMSCs	NULL
)	NULL
are	NULL
the	NULL
major	NULL
source	NULL
of	NULL
IL-6	NULL
in	NULL
MM	NULL
``	NULL
;	NULL
freshly	NULL
isolated	NULL
MM	NULL
cells	NULL
cultured	NULL
without	NULL
exogenous	NULL
IL-6	NULL
rapidly	NULL
stop	NULL
pro-liferating'*	NULL
;	NULL
and	NULL
adhesion	NULL
of	NULL
MM	NULL
cells	NULL
to	NULL
BMSCs	NULL
upregulates	NULL
IL-6	NULL
secretion	NULL
by	NULL
BMSCs	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Most	NULL
recently	NULL
,	NULL
IL-6	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
survival	NULL
of	NULL
MM	NULL
cells	NULL
,	NULL
because	NULL
it	NULL
can	NULL
inhibit	NULL
apoptosis	NULL
of	NULL
tumor	NULL
cells	NULL
induced	NULL
by	NULL
corticosteroids	NULL
,	NULL
``	NULL
serum	NULL
starvation	NULL
,	NULL
'	NULL
``	NULL
``	NULL
and	NULL
anti-Fas	NULL
.	NULL
``	NULL

There	NULL
is	NULL
also	NULL
considerable	NULL
evidence	NULL
supporting	NULL
a	NULL
role	NULL
for	NULL
IL-6	NULL
in	NULL
the	NULL
growth	NULL
and	NULL
manifestations	NULL
of	NULL
MM	NULL
in	NULL
vivo	NULL
:	NULL
elevated	NULL
IL-6	NULL
serum	NULL
levels	NULL
correlate	NULL
with	NULL
poor	NULL
prognosis	NULL
and	NULL
higher	NULL
tumor	NULL
cell	NULL
mass	NULL
in	NULL
MM	NULL
;	NULL
IL-6	NULL
transgenic	NULL
mice	NULL
develop	NULL
histopathologic	NULL
changes	NULL
characteristic	NULL
of	NULL
MM	NULL
kidney	NULL
;	NULL
IL-6	NULL
serves	NULL
an	NULL
as	NULL
osteoclast	NULL
activating	NULL
factor	NULL
in	NULL
MM	NULL
bone	NULL
disease	NULL
;	NULL
and	NULL
anti-IL-6	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
therapy	NULL
can	NULL
transiently	NULL
reverse	NULL
disease	NULL
manifestations	NULL
in	NULL
patients	NULL
with	NULL
MM	NULL
.	NULL

***	NULL
Despite	NULL
this	NULL
central	NULL
role	NULL
for	NULL
IL-6	NULL
in	NULL
MM	NULL
cell	NULL
growth	NULL
,	NULL
some	NULL
patient	NULL
MM	NULL
cells	NULL
and	NULL
derived	NULL
cell	NULL
lines	NULL
that	NULL
bear	NULL
IL-6	NULL
receptors	NULL
grow	NULL
independently	NULL
of	NULL
IL-6	NULL
.	NULL

Moreover	NULL
,	NULL
although	NULL
overproduction	NULL
of	NULL
IL-6	NULL
in	NULL
vivo	NULL
can	NULL
occur	NULL
in	NULL
MM	NULL
,	NULL
it	NULL
is	NULL
also	NULL
observed	NULL
in	NULL
other	NULL
diseases	NULL
including	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
Castleman	NULL
's	NULL
disease	NULL
,	NULL
mesangial	NULL
proliferative	NULL
glomerulone-phritis	NULL
,	NULL
and	NULL
cardiac	NULL
myxoma	NULL
.	NULL
``	NULL

Patients	NULL
with	NULL
these	NULL
diseases	NULL
do	NULL
not	NULL
develop	NULL
MM	NULL
,	NULL
suggesting	NULL
that	NULL
additional	NULL
factors	NULL
are	NULL
essential	NULL
for	NULL
MM	NULL
pathogenesis	NULL
.	NULL

Studies	NULL
in	NULL
animals	NULL
suggest	NULL
that	NULL
genetic	NULL
abnormalities	NULL
,	NULL
which	NULL
result	NULL
in	NULL
a	NULL
pathological	NULL
response	NULL
to	NULL
IL-6	NULL
,	NULL
may	NULL
be	NULL
required	NULL
for	NULL
development	NULL
of	NULL
MM	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
88	NULL
,	NULL
No	NULL
6	NULL
(	NULL
September	NULL
15	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
2219-2227	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
proliferation	NULL
was	NULL
only	NULL
partially	NULL
inhibited	NULL
by	NULL
neutralizing	NULL
anti-IL-6	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
.	NULL

in	NULL
contrast	NULL
to	NULL
MM	NULL
cells	NULL
,	NULL
normai	NULL
splenic	NULL
B	NULL
cells	NULL
express	NULL
dephosphorylated	NULL
pRB	NULL
.	NULL

Although	NULL
CD40	NULL
ligand	NULL
(	NULL
CD4OL	NULL
)	NULL
triggers	NULL
a	NULL
shift	NULL
from	NULL
dephosphorylated	NULL
to	NULL
phosphorylated	NULL
pRB	NULL
and	NULL
proliferation	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-6	NULL
to	NULL
CD40L-treated	NULL
B	NULL
cells	NULL
does	NULL
not	NULL
alter	NULL
either	NULL
pRB	NULL
or	NULL
proliferation	NULL
,	NULL
as	NULL
observed	NULL
in	NULL
MM	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
phosphorylated	NULL
pRB	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
MM	NULL
cells	NULL
and	NULL
that	NULL
IL-6	NULL
further	NULL
shifts	NULL
pRB	NULL
from	NULL
its	NULL
dephosphorylated	NULL
to	NULL
its	NULL
phosphorylated	NULL
form	NULL
,	NULL
thereby	NULL
promoting	NULL
MM	NULL
cell	NULL
growth	NULL
via	NULL
two	NULL
mechanisms	NULL
:	NULL
by	NULL
decreasing	NULL
the	NULL
amount	NULL
of	NULL
E2F	NULL
bound	NULL
by	NULL
dephosphorylated	NULL
pRB	NULL
due	NULL
to	NULL
reduced	NULL
dephosphorylated	NULL
pRB	NULL
,	NULL
thereby	NULL
releasing	NULL
growth	NULL
arrest	NULL
;	NULL
and	NULL
by	NULL
upregulating	NULL
IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
cells	NULL
and	NULL
related	NULL
IL-6-mediated	NULL
autocrine	NULL
tumor	NULL
cell	NULL
growth	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

For	NULL
example	NULL
,	NULL
plasmacytomas	NULL
can	NULL
grow	NULL
in	NULL
wild	NULL
type	NULL
mice	NULL
,	NULL
but	NULL
not	NULL
in	NULL
IL-6	NULL
knock	NULL
out	NULL
littermates	NULL
,	NULL
``	NULL
confirming	NULL
the	NULL
essential	NULL
role	NULL
of	NULL
IL-6	NULL
.	NULL

However	NULL
,	NULL
C57BL/6	NULL
IL-6	NULL
transgenic	NULL
mice	NULL
develop	NULL
massive	NULL
plasmacytosis	NULL
without	NULL
plasmacytomas	NULL
,	NULL
``	NULL
``	NULL
whereas	NULL
BALB/C	NULL
IL-6	NULL
transgenic	NULL
mice	NULL
develop	NULL
transplant	NULL
able	NULL
monoclonal	NULL
plasmacytomas	NULL
.	NULL
``	NULL

''	NULL
These	NULL
animal	NULL
studies	NULL
confirm	NULL
that	NULL
IL-6	NULL
can	NULL
enhance	NULL
susceptibility	NULL
to	NULL
either	NULL
plasmacytosis	NULL
and	NULL
Ab	NULL
formation	NULL
or	NULL
the	NULL
development	NULL
and	NULL
growth	NULL
of	NULL
plasmacytomas	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
genetic	NULL
background	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
gene	NULL
contribute	NULL
to	NULL
cellular	NULL
transformation	NULL
in	NULL
many	NULL
types	NULL
of	NULL
malignancies	NULL
.	NULL

Specifically	NULL
,	NULL
normal	NULL
retinoblastoma	NULL
protein	NULL
(	NULL
pRB	NULL
)	NULL
suppresses	NULL
the	NULL
transition	NULL
from	NULL
G1	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
``	NULL
*	NULL
``	NULL
°	NULL
by	NULL
inhibiting	NULL
E2F-mediated	NULL
transactivation	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
initiating	NULL
DNA	NULL
synthesis	NULL
,	NULL
ie	NULL
,	NULL
c-myc	NULL
,	NULL
b-myb	NULL
,	NULL
cdc2	NULL
,	NULL
dihydrofolate	NULL
reductase	NULL
,	NULL
and	NULL
thymidine	NULL
kinase	NULL
.	NULL
``	NULL

pRB	NULL
function	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
:	NULL
hypo	NULL
or	NULL
dephosphorylated	NULL
(	NULL
activated	NULL
)	NULL
pRB	NULL
binds	NULL
E2F	NULL
and	NULL
induces	NULL
G1	NULL
growth	NULL
arrest	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
phosphorylated	NULL
(	NULL
inactivated	NULL
)	NULL
pRB	NULL
can	NULL
not	NULL
bind	NULL
E2F	NULL
,	NULL
thereby	NULL
facilitating	NULL
entry	NULL
of	NULL
cells	NULL
into	NULL
S	NULL
phase	NULL
.	NULL
``	NULL

To	NULL
date	NULL
mutations	NULL
in	NULL
RB	NULL
gene	NULL
or	NULL
abnormalities	NULL
in	NULL
pRB	NULL
have	NULL
been	NULL
noted	NULL
in	NULL
up	NULL
to	NULL
70	NULL
%	NULL
of	NULL
MM	NULL
patients	NULL
and	NULL
80	NULL
%	NULL
of	NULL
MM-derived	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
Moreover	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
From	NULL
the	NULL
Divisions	NULL
of	NULL
Hematologic	NULL
Malignancies	NULL
and	NULL
Neoplastic	NULL
Disease	NULL
Mechanisms	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
Boston	NULL
,	NULL
MA	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Jikei	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
.	NULL

Submitted	NULL
January	NULL
25	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
May	NULL
8	NULL
,	NULL
1996	NULL
.	NULL

Supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Grant	NULL
No	NULL
.	NULL

CA	NULL
50947	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Kenneth	NULL
C.	NULL
Anderson	NULL
,	NULL
MD	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
44	NULL
Binney	NULL
St	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02215	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/96/8806-001	NULL
1	NULL
$	NULL
3.00/0	NULL
2219	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2220	NULL
reported	NULL
that	NULL
transforming	NULL
growth	NULL
factor	NULL
(	NULL
TGF	NULL
/3	NULL
)	NULL
does	NULL
not	NULL
suppress	NULL
phosphorylation	NULL
of	NULL
pRB	NULL
and	NULL
proliferation	NULL
of	NULL
MM	NULL
cells	NULL
,	NULL
``	NULL
as	NULL
occurs	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
view	NULL
that	NULL
pRB	NULL
may	NULL
contribute	NULL
to	NULL
MM	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
it	NULL
is	NULL
known	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
MM	NULL
cells	NULL
and	NULL
derived	NULL
cell	NULL
lines	NULL
express	NULL
IL-6	NULL
receptors	NULL
,	NULL
and	NULL
yet	NULL
only	NULL
a	NULL
subset	NULL
are	NULL
dependent	NULL
on	NULL
IL-6	NULL
for	NULL
growth	NULL
``	NULL
``	NULL
;	NULL
it	NULL
is	NULL
,	NULL
therefore	NULL
,	NULL
possible	NULL
that	NULL
abnormalities	NULL
in	NULL
cell	NULL
cycle	NULL
regulatory	NULL
proteins	NULL
,	NULL
ie	NULL
,	NULL
RB	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
MM	NULL
cell	NULL
growth	NULL
and	NULL
progressive	NULL
disease	NULL
.	NULL

In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
characterized	NULL
the	NULL
role	NULL
of	NULL
pRB	NULL
in	NULL
IL-6-mediated	NULL
MM	NULL
cell	NULL
growth	NULL
.	NULL

Although	NULL
both	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
were	NULL
expressed	NULL
in	NULL
all	NULL
serum-starved	NULL
MM	NULL
patient	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
pRB	NULL
was	NULL
predominantly	NULL
in	NULL
its	NULL
phosphorylated	NULL
form	NULL
.	NULL

Exogenous	NULL
IL-6	NULL
downregulated	NULL
dephosphorylated	NULL
pRB	NULL
and	NULL
decreased	NULL
dephosphorylated	NULL
pRB	NULL
to	NULL
E2F	NULL
complexes	NULL
in	NULL
MM	NULL
cells	NULL
,	NULL
Culture	NULL
of	NULL
MM	NULL
cells	NULL
with	NULL
RB	NULL
antisense	NULL
,	NULL
but	NULL
not	NULL
RB	NULL
sense	NULL
,	NULL
oligonucleotide	NULL
(	NULL
ODN	NULL
)	NULL
triggered	NULL
IL-6	NULL
secretion	NULL
and	NULL
proliferation	NULL
in	NULL
MM	NULL
cells	NULL
;	NULL
the	NULL
latter	NULL
was	NULL
partially	NULL
inhibited	NULL
by	NULL
neutralizing	NULL
anti-IL-6	NULL
MoAb	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
dephosphorylated	NULL
and	NULL
phosphorylated	NULL
pRB	NULL
are	NULL
present	NULL
,	NULL
and	NULL
that	NULL
the	NULL
former	NULL
induces	NULL
growth	NULL
arrest	NULL
,	NULL
even	NULL
though	NULL
the	NULL
latter	NULL
predominates	NULL
.	NULL

However	NULL
,	NULL
in	NULL
IL-6-responsive	NULL
MM	NULL
cells	NULL
,	NULL
IL-6	NULL
further	NULL
shifts	NULL
pRB	NULL
from	NULL
its	NULL
dephosphorylated	NULL
to	NULL
its	NULL
phosphorylated	NULL
form	NULL
,	NULL
thereby	NULL
promoting	NULL
MM	NULL
cell	NULL
growth	NULL
via	NULL
two	NULL
mechanisms	NULL
:	NULL
by	NULL
decreasing	NULL
binding	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
to	NULL
E2F	NULL
and	NULL
releasing	NULL
growth	NULL
arrest	NULL
,	NULL
and	NULL
by	NULL
upregulating	NULL
IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
cells	NULL
and	NULL
IL-6-mediated	NULL
autocrine	NULL
tumor	NULL
cell	NULL
growth	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
MM	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
.	NULL

-	NULL
Mononuclear	NULL
cells	NULL
(	NULL
MCs	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
three	NULL
patients	NULL
with	NULL
MM	NULL
by	NULL
Ficoll-Hypaque	NULL
(	NULL
FH	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
,	NULL
incubated	NULL
with	NULL
HB7	NULL
(	NULL
anti-CD38	NULL
)	NULL
MoAb-biotin-streptavidin	NULL
and	NULL
2H4	NULL
(	NULL
anti-CD45RA	NULL
)	NULL
MoAb-fluores-cein	NULL
isothiocyanate	NULL
on	NULL
ice	NULL
.	NULL

MM	NULL
cells	NULL
(	NULL
96	NULL
%	NULL
+	NULL
2	NULL
%	NULL
CD38*	NULL
were	NULL
isolated	NULL
using	NULL
an	NULL
Epics	NULL
C	NULL
Cell	NULL
Sorter	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI-1640	NULL
media	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
,	NULL
L-glutamine	NULL
(	NULL
L-glu	NULL
)	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
100	NULL
U/mL	NULL
penicillin	NULL
(	NULL
pen	NULL
)	NULL
,	NULL
and	NULL
100	NULL
ug/mL	NULL
streptomycin	NULL
(	NULL
strep	NULL
)	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

The	NULL
ARH-77	NULL
,	NULL
IM-9	NULL
,	NULL
RPMI-8226	NULL
,	NULL
and	NULL
U-266	NULL
human	NULL
MM-derived	NULL
cell	NULL
lines	NULL
'	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rock-ville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
XG-1	NULL
IL-6-dependent	NULL
MM	NULL
cell	NULL
line	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Bernard	NULL
Klein	NULL
(	NULL
Institute	NULL
for	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Montpellier	NULL
,	NULL
France	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
media	NULL
with	NULL
1	NULL
ng/mL	NULL
of	NULL
IL-6	NULL
(	NULL
Kirin-Brewrey	NULL
Co	NULL
Ltd	NULL
,	NULL
Minato-ku	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL
``	NULL

The	NULL
U-1958	NULL
``	NULL
and	NULL
OCI-My5®	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Drs	NULL
Kenneth	NULL
Nilsson	NULL
(	NULL
Uppsala	NULL
University	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
H.A	NULL
.	NULL

Messner	NULL
(	NULL
Ontario	NULL
Cancer	NULL
Institute	NULL
,	NULL
Toronto	NULL
,	NULL
Ontario	NULL
,	NULL
Canada	NULL
)	NULL
.	NULL

The	NULL
JKB	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
ALL	NULL
)	NULL
,	NULL
``	NULL
an	NULL
IL-6	NULL
nonresponsive	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
the	NULL
CMK	NULL
acute	NULL
megakaryocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
``	NULL
``	NULL
*	NULL
``	NULL
which	NULL
grows	NULL
in	NULL
an	NULL
IL-6-mediated	NULL
autocrine	NULL
fashion	NULL
,	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
the	NULL
MM	NULL
cells/MM	NULL
derived	NULL
cell	NULL
lines	NULL
.	NULL

B-cell	NULL
preparation	NULL
and	NULL
culture	NULL
.	NULL

-	NULL
Normal	NULL
spleen	NULL
(	NULL
n	NULL
=	NULL
5	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
operative	NULL
specimens	NULL
of	NULL
patients	NULL
not	NULL
known	NULL
to	NULL
have	NULL
any	NULL
systemic	NULL
or	NULL
malignant	NULL
diseases	NULL
.	NULL

Single	NULL
cell	NULL
suspensions	NULL
from	NULL
spleen	NULL
were	NULL
prepared	NULL
by	NULL
extrusion	NULL
through	NULL
sterile	NULL
stainless	NULL
steel	NULL
mesh	NULL
.	NULL

Splenic	NULL
MC	NULL
's	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
FH	NULL
density	NULL
sedimen-tation	NULL
,	NULL
and	NULL
adherent	NULL
cells	NULL
removed	NULL
from	NULL
MCs	NULL
by	NULL
double	NULL
adherence	NULL
to	NULL
plastic	NULL
petri	NULL
dishes	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
37°C	NULL
.	NULL

Further	NULL
enrichment	NULL
for	NULL
B	NULL
cells	NULL
in	NULL
spleen	NULL
was	NULL
done	NULL
by	NULL
rosetting	NULL
with	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
to	NULL
URASHIMA	NULL
ET	NULL
AL	NULL
deplete	NULL
T	NULL
cells	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
media	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
L-glu	NULL
,	NULL
and	NULL
pen/strep	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Splenic	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
B1	NULL
>	NULL
90	NULL
%	NULL
(	NULL
++	NULL
)	NULL
,	NULL
B2	NULL
>	NULL
85	NULL
%	NULL
(	NULL
++	NULL
)	NULL
,	NULL
CD38	NULL
negative	NULL
,	NULL
PCA-1	NULL
negative	NULL
,	NULL
gp	NULL
80	NULL
and	NULL
gp130	NULL
IL-6	NULL
receptor	NULL
(	NULL
IL-6R	NULL
)	NULL
negative	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
,	NULL
were	NULL
cultured	NULL
with	NULL
soluble	NULL
CD4O0L	NULL
(	NULL
1:4	NULL
dilution	NULL
)	NULL
for	NULL
7	NULL
days	NULL
to	NULL
trigger	NULL
their	NULL
differentiation	NULL
to	NULL
8	NULL
%	NULL
BI	NULL
(	NULL
+	NULL
)	NULL
,	NULL
B2	NULL
negative	NULL
,	NULL
85	NULL
%	NULL
CD38	NULL
(	NULL
++	NULL
)	NULL
,	NULL
47	NULL
%	NULL
PCA-1	NULL
(	NULL
++	NULL
)	NULL
,	NULL
22	NULL
%	NULL
gp80	NULL
(	NULL
+	NULL
)	NULL
,	NULL
and	NULL
55	NULL
%	NULL
gp130	NULL
(	NULL
++	NULL
)	NULL
,	NULL
as	NULL
in	NULL
previous	NULL
studies	NULL
.	NULL
``	NULL

Assays	NULL
of	NULL
DNA	NULL
synthesis	NULL
.	NULL

-	NULL
DNA	NULL
synthesis	NULL
was	NULL
measured	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
%	NULL
/well	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
96-well	NULL
plates	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
media	NULL
,	NULL
IL-6	NULL
or	NULL
CD4O0L	NULL
,	NULL
and	NULL
DNA	NULL
synthesis	NULL
measured	NULL
using	NULL
*H-thymidine	NULL
(	NULL
°H-TdR	NULL
)	NULL
uptake	NULL
.	NULL

Cells	NULL
were	NULL
pulsed	NULL
with	NULL
°H-TdR	NULL
(	NULL
1	NULL
Ci/well	NULL
)	NULL
during	NULL
the	NULL
last	NULL
6	NULL
hours	NULL
of	NULL
2-day	NULL
and	NULL
last	NULL
18	NULL
hours	NULL
of	NULL
4-day	NULL
cultures	NULL
,	NULL
harvested	NULL
onto	NULL
glass	NULL
filters	NULL
with	NULL
an	NULL
automatic	NULL
cell	NULL
harvester	NULL
(	NULL
Cambridge	NULL
Technology	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
and	NULL
counted	NULL
on	NULL
a	NULL
liquid	NULL
scintillation	NULL
counter	NULL
(	NULL
Packard	NULL
Tri-Carb	NULL
4530	NULL
,	NULL
Downers	NULL
Grove	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Stimulation	NULL
index	NULL
(	NULL
SD	NULL
)	NULL
was	NULL
calculated	NULL
as	NULL
°H-TdR	NULL
uptake	NULL
of	NULL
cells	NULL
with	NULL
uptake	NULL
of	NULL
cells	NULL
with	NULL
media	NULL
alone	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
Western	NULL
immunoblotting	NULL
.	NULL

-	NULL
Immunoprecipitation	NULL
and	NULL
Western	NULL
immunoblotting	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
reported	NULL
.	NULL
``	NULL

''	NULL
For	NULL
immunoprecipitation	NULL
(	NULL
IP	NULL
)	NULL
of	NULL
pRB	NULL
,	NULL
as	NULL
well	NULL
as	NULL
E2F	NULL
,	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/sample	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
media	NULL
without	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
before	NULL
,	NULL
as	NULL
well	NULL
as	NULL
at	NULL
30	NULL
and	NULL
240	NULL
minutes	NULL
after	NULL
,	NULL
culture	NULL
with	NULL
IL-6	NULL
(	NULL
100	NULL
ng/	NULL
mL	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
phosphate	NULL
buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
lysed	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
in	NULL
buffer	NULL
:	NULL
10	NULL
mmol/L	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
Noidet	NULL
P-40	NULL
,	NULL
5	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
PMSF	NULL
,	NULL
200	NULL
mmol/L	NULL
Na	NULL
,	NULL
;	NULL
VO,4	NULL
,	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
NaF	NULL
.	NULL

Murine	NULL
anti-pRB	NULL
MoAb	NULL
(	NULL
Oncogene	NULL
Science	NULL
,	NULL
Union-dale	NULL
,	NULL
NY	NULL
)	NULL
or	NULL
rabbit	NULL
anti-E2F	NULL
polyclonal	NULL
Ab	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnol-ogy	NULL
,	NULL
Santa	NULL
Cruz	NULL
CA	NULL
)	NULL
was	NULL
added	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Proteins	NULL
were	NULL
collected	NULL
using	NULL
protein	NULL
G	NULL
sepharose	NULL
for	NULL
murine	NULL
Ab	NULL
or	NULL
protein	NULL
A	NULL
sepharose	NULL
for	NULL
rabbit	NULL
Ab	NULL
.	NULL

Aliquots	NULL
of	NULL
each	NULL
lysate	NULL
were	NULL
analyzed	NULL
by	NULL
5.0	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
elec-trophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
.	NULL

Protein	NULL
was	NULL
transferred	NULL
onto	NULL
nitrocellulose	NULL
membrane	NULL
,	NULL
and	NULL
nonspecific	NULL
binding	NULL
was	NULL
blocked	NULL
by	NULL
incubation	NULL
with	NULL
5	NULL
%	NULL
skim	NULL
milk	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
probed	NULL
with	NULL
anti-pRB	NULL
or	NULL
with	NULL
murine	NULL
anti-E2F	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
MoAb	NULL
,	NULL
incubated	NULL
with	NULL
antimouse	NULL
Ig	NULL
Abs	NULL
conjugated	NULL
with	NULL
horse	NULL
radish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
and	NULL
detected	NULL
using	NULL
the	NULL
enhanced	NULL
chemilumi-nescence	NULL
(	NULL
ECL	NULL
)	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Sense	NULL
and	NULL
antisense	NULL
oligonucleotides	NULL
.	NULL

_	NULL
A	NULL
15-base	NULL
antisense	NULL
ODN	NULL
specific	NULL
for	NULL
a	NULL
sequence	NULL
of	NULL
RB	NULL
gene	NULL
(	NULL
5'-GGT	NULL
TTT	NULL
GGG	NULL
CGG	NULL
CAT-3	NULL
'	NULL
)	NULL
previously	NULL
effective	NULL
in	NULL
enhancing	NULL
growth	NULL
in	NULL
keratinocytes	NULL
,	NULL
``	NULL
as	NULL
well	NULL
as	NULL
complementary	NULL
sense	NULL
ODN	NULL
(	NULL
5'-ATG	NULL
CCG	NULL
CCC	NULL
AAA	NULL
ACC-3	NULL
'	NULL
)	NULL
,	NULL
was	NULL
added	NULL
to	NULL
cultures	NULL
of	NULL
MM	NULL
cells	NULL
.	NULL

ODNs	NULL
were	NULL
synthesized	NULL
by	NULL
cyanoethyl	NULL
phosphoramide	NULL
methodology	NULL
,	NULL
purified	NULL
by	NULL
Sephadex	NULL
column	NULL
and	NULL
ethanol	NULL
precipitation	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
sterile	NULL
water	NULL
.	NULL

They	NULL
were	NULL
added	NULL
to	NULL
MM	NULL
cell	NULL
cultures	NULL
at	NULL
concentrations	NULL
between	NULL
0.1	NULL
and	NULL
10	NULL
pmol/L	NULL
and	NULL
replenished	NULL
daily	NULL
.	NULL

Proliferation	NULL
and	NULL
IL-6	NULL
secretion	NULL
were	NULL
measured	NULL
in	NULL
MM	NULL
cultures	NULL
with	NULL
RB	NULL
sense	NULL
or	NULL
RB	NULL
antisense	NULL
ODN	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
neutralizing	NULL
anti-IL-6	NULL
MoAb	NULL
.	NULL

Measurement	NULL
of	NULL
IL-6	NULL
secretion	NULL
.	NULL

-	NULL
IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
patient	NULL
cells	NULL
cultured	NULL
in	NULL
media	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RB	NULL
sense	NULL
or	NULL
RB	NULL
antisense	NULL
ODNs	NULL
was	NULL
measured	NULL
using	NULL
an	NULL
Enzyme	NULL
linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

''	NULL
Briefly	NULL
,	NULL
(	NULL
1	NULL
)	NULL
96-well	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
were	NULL
coated	NULL
with	NULL
anti-IL-6	NULL
MoAb	NULL
(	NULL
mu-rine	NULL
IgG1L	NULL
,	NULL
Toray	NULL
,	NULL
Ohtsu-shi	NULL
,	NULL
Shiga	NULL
,	NULL
Japan	NULL
)	NULL
;	NULL
(	NULL
2	NULL
)	NULL
wells	NULL
were	NULL
saturated	NULL
with	NULL
calfskin	NULL
gelatin	NULL
(	NULL
BioRad	NULL
,	NULL
Melville	NULL
,	NULL
NY	NULL
)	NULL
-PBS	NULL
for	NULL
1	NULL
hour	NULL
;	NULL
(	NULL
3	NULL
)	NULL
serial	NULL
dilutions	NULL
(	NULL
100	NULL
gL	NULL
)	NULL
of	NULL
test	NULL
sample	NULL
supernatants	NULL
were	NULL
added	NULL
in	NULL
duplicate	NULL
to	NULL
plates	NULL
;	NULL
and	NULL
(	NULL
4	NULL
)	NULL
biotinylated	NULL
detector	NULL
anti-IL-6	NULL
MoAb	NULL
(	NULL
Genetics	NULL
Institute	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
was	NULL
added	NULL
and	NULL
developed	NULL
with	NULL
avidin-peroxidase	NULL
(	NULL
Amersham	NULL
)	NULL
,	NULL
tetramethylbenzidine	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-6	NULL
AND	NULL
RB	NULL
IN	NULL
MULTIPLE	NULL
MYELOMA	NULL
2221	NULL
Table	NULL
1	NULL
.	NULL

Effects	NULL
of	NULL
IL-6	NULL
on	NULL
Call	NULL
Proliferation	NULL
Stimulation	NULL
Index*	NULL
Concentrations	NULL
of	NULL
IL-6	NULL
(	NULL
ng/mL	NULL
)	NULL
xXG-1	NULL
Patient	NULL
1	NULL
Patient	NULL
2	NULL
Patient	NULL
3	NULL
OCI-My§S	NULL
U-266	NULL
U-1958	NULL
0	NULL
1.0	NULL
+	NULL
0.2	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.0	NULL
1	NULL
2.0	NULL
+	NULL
0.3	NULL
2.8	NULL
+	NULL
0.2	NULL
2.1	NULL
+	NULL
0.1	NULL
13.4	NULL
+	NULL
2.1	NULL
1.4	NULL
#	NULL
0.1	NULL
1.4	NULL
+	NULL
0.1	NULL
1.5	NULL
+	NULL
0.1	NULL
10	NULL
3.3	NULL
+	NULL
0.3	NULL
3.1	NULL
+	NULL
0.3	NULL
2.9	NULL
+	NULL
0.2	NULL
22.5	NULL
+	NULL
3.1	NULL
1.6	NULL
+	NULL
0.3	NULL
1.5	NULL
+	NULL
0.1	NULL
1.6	NULL
+	NULL
0.1	NULL
100	NULL
5.4	NULL
+	NULL
1.0	NULL
4.6	NULL
+	NULL
0.3	NULL
3.3	NULL
+	NULL
0.2	NULL
25.4	NULL
+	NULL
3.1	NULL
1.9	NULL
+	NULL
0.3	NULL
1.6	NULL
+	NULL
0.1	NULL
1.6	NULL
+	NULL
0.1	NULL
CMK	NULL
ARHK-77	NULL
RPMI-8226	NULL
IM-9	NULL
JKB	NULL
B	NULL
Cells	NULL
CDA40L	NULL
+	NULL
B	NULL
Cells	NULL
0	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.0	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
*	NULL
0.1	NULL
1	NULL
1.1	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.1	NULL
1.1	NULL
+	NULL
0.0	NULL
1.0	NULL
+	NULL
0.0	NULL
1.0	NULL
+	NULL
0.0	NULL
1.0	NULL
+	NULL
0.1	NULL
10	NULL
1.5	NULL
+	NULL
0.1	NULL
1.2	NULL
+	NULL
0.1	NULL
1.2	NULL
+	NULL
0.0	NULL
1.1	NULL
+	NULL
0.0	NULL
1.1	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.0	NULL
1.0	NULL
+	NULL
0.2	NULL
100	NULL
1.9	NULL
+	NULL
0.1	NULL
1.3	NULL
+	NULL
0.1	NULL
1.2	NULL
+	NULL
0.1	NULL
1.2	NULL
+	NULL
0.0	NULL
1.1	NULL
+	NULL
0.1	NULL
1.0	NULL
+	NULL
0.0	NULL
1.0	NULL
£	NULL
0.1	NULL
Data	NULL
shown	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

*	NULL
Stimulation	NULL
index	NULL
(	NULL
Sl	NULL
)	NULL
=	NULL
°H-TdR	NULL
uptake	NULL
of	NULL
cells	NULL
with	NULL
IL-6/3H-TdR	NULL
uptake	NULL
of	NULL
cells	NULL
in	NULL
media	NULL
alone	NULL
.	NULL

30	NULL
%	NULL
peroxide	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
minimal	NULL
detectable	NULL
level	NULL
of	NULL
IL-6	NULL
was	NULL
10	NULL
pg/mL	NULL
.	NULL

Reagents	NULL
.	NULL

IL-6	NULL
(	NULL
Kirin-Brewrey	NULL
Co	NULL
Ltd	NULL
)	NULL
was	NULL
added	NULL
to	NULL
cultures	NULL
of	NULL
patient	NULL
MM	NULL
cells	NULL
,	NULL
MM	NULL
or	NULL
other	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
effects	NULL
on	NULL
cell	NULL
proliferation	NULL
and	NULL
phosphorylation	NULL
state	NULL
of	NULL
pRB	NULL
were	NULL
assayed	NULL
.	NULL

Anti-IL-6	NULL
MoAb	NULL
(	NULL
Genetics	NULL
Institute	NULL
)	NULL
or	NULL
unreactive	NULL
isomatched	NULL
(	NULL
IgG1	NULL
)	NULL
control	NULL
MoAb	NULL
(	NULL
Coulter	NULL
)	NULL
was	NULL
added	NULL
to	NULL
cultures	NULL
of	NULL
MM	NULL
cells	NULL
with	NULL
RB	NULL
sense	NULL
or	NULL
antisense	NULL
ODN	NULL
.	NULL

Soluble	NULL
CD40L	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Diane	NULL
Hollenbaugh	NULL
(	NULL
Bristol-Myers	NULL
Squibb	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
CD4O0L	NULL
gene	NULL
was	NULL
transfected	NULL
into	NULL
COS	NULL
cells	NULL
and	NULL
supernatants	NULL
harvested	NULL
and	NULL
characterized	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Soluble	NULL
CD40L	NULL
was	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1:4	NULL
dilution	NULL
,	NULL
previously	NULL
shown	NULL
to	NULL
trigger	NULL
splenic	NULL
B-cell	NULL
proliferation	NULL
.	NULL
``	NULL

RESULTS	NULL
Effects	NULL
of	NULL
IL-6	NULL
on	NULL
DNA	NULL
synthesis	NULL
by	NULL
MM	NULL
cells/MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
CD4OL-treated	NULL
B	NULL
cells	NULL
.	NULL

MM	NULL
patient	NULL
cells/	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
media	NULL
free	NULL
of	NULL
FBS	NULL
.	NULL

DNA	NULL
synthesis	NULL
was	NULL
measured	NULL
using	NULL
°H-TdR	NULL
uptake	NULL
during	NULL
the	NULL
last	NULL
6	NULL
hours	NULL
of	NULL
day	NULL
2	NULL
cultures	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Proliferation	NULL
of	NULL
IL-6-dependent	NULL
XG-1	NULL
cells	NULL
and	NULL
of	NULL
patient	NULL
MM	NULL
cells	NULL
was	NULL
directly	NULL
correlated	NULL
with	NULL
IL-6	NULL
concentration	NULL
.	NULL

For	NULL
XG-1	NULL
cells	NULL
and	NULL
MM	NULL
cells	NULL
from	NULL
patients	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
,	NULL
culture	NULL
with	NULL
100	NULL
ng/mL	NULL
of	NULL
IL-6	NULL
increased	NULL
°H-TdR	NULL
uptake	NULL
:	NULL
SI	NULL
5.4	NULL
P	NULL
<	NULL
005	NULL
,	NULL
SIT	NULL
4.6	NULL
P	NULL
<	NULL
.005	NULL
,	NULL
SI	NULL
3.3	NULL
P	NULL
<	NULL
.005	NULL
,	NULL
and	NULL
25.4	NULL
P	NULL
<	NULL
.001	NULL
,	NULL
respectively	NULL
.	NULL

IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
also	NULL
stimulated	NULL
low	NULL
level	NULL
but	NULL
reproducible	NULL
proliferation	NULL
of	NULL
other	NULL
MM	NULL
cell	NULL
lines	NULL
:	NULL
SI	NULL
1.6	NULL
P	NULL
<	NULL
.05	NULL
,	NULL
SI	NULL
1.6	NULL
P	NULL
<	NULL
.01	NULL
,	NULL
and	NULL
SI	NULL
1.9	NULL
P	NULL
<	NULL
.01	NULL
for	NULL
U-266	NULL
,	NULL
U-1958	NULL
,	NULL
and	NULL
OCI-My5	NULL
MM	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

Significant	NULL
proliferation	NULL
of	NULL
RPMI-8226	NULL
,	NULL
IM-9	NULL
,	NULL
and	NULL
ARH-77	NULL
MM	NULL
cells	NULL
to	NULL
IL-6	NULL
was	NULL
not	NULL
observed	NULL
under	NULL
any	NULL
conditions	NULL
.	NULL

The	NULL
CMK	NULL
megakaryocytic	NULL
cell	NULL
line	NULL
also	NULL
proliferated	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
(	NULL
SI	NULL
1.9	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
JKB	NULL
ALL	NULL
cells	NULL
did	NULL
not	NULL
increase	NULL
DNA	NULL
synthesis	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
.	NULL

CD4O0L	NULL
stimulated	NULL
proliferation	NULL
of	NULL
splenic	NULL
B	NULL
cells	NULL
(	NULL
SI	NULL
:	NULL
3.1	NULL
,	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
,	NULL
but	NULL
IL-6	NULL
did	NULL
not	NULL
alter	NULL
*H-TdR	NULL
uptake	NULL
in	NULL
either	NULL
splenic	NULL
B	NULL
cells	NULL
or	NULL
CD40L-treated	NULL
splenic	NULL
B	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
IL-6	NULL
on	NULL
phosphorylation	NULL
of	NULL
pRB	NULL
in	NULL
MM	NULL
patient	NULL
cells/MM	NULL
cell	NULL
lines	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
CD4OL-treated	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
IL-6	NULL
on	NULL
phosphorylation	NULL
state	NULL
of	NULL
pRB	NULL
was	NULL
investigated	NULL
using	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
immunoblotting	NULL
.	NULL

Phosphorylation	NULL
slows	NULL
electrophoretic	NULL
mobility	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
upper	NULL
(	NULL
115	NULL
kD	NULL
)	NULL
band	NULL
corresponds	NULL
to	NULL
phosphor	NULL
ylated	NULL
pRB	NULL
and	NULL
the	NULL
lower	NULL
(	NULL
105	NULL
kD	NULL
)	NULL
band	NULL
to	NULL
de-	NULL
or	NULL
hypophos-phorylated	NULL
pRB	NULL
.	NULL

Multiple	NULL
bands	NULL
between	NULL
105	NULL
kD	NULL
and	NULL
115	NULL
kD	NULL
represent	NULL
several	NULL
forms	NULL
of	NULL
pRB	NULL
that	NULL
are	NULL
phosphorylated	NULL
at	NULL
different	NULL
sites	NULL
or	NULL
with	NULL
different	NULL
stoichiometry	NULL
.	NULL
``	NULL

Both	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
were	NULL
ob-served	NULL
,	NULL
at	NULL
115	NULL
kD	NULL
and	NULL
105	NULL
kD	NULL
respectively	NULL
,	NULL
in	NULL
all	NULL
MM	NULL
patient	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
after	NULL
serum	NULL
starvation	NULL
for	NULL
48	NULL
hours	NULL
;	NULL
however	NULL
,	NULL
phosphorylated	NULL
pRB	NULL
was	NULL
predominant	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Even	NULL
after	NULL
serum	NULL
starvation	NULL
for	NULL
72	NULL
hours	NULL
,	NULL
phosphorylated	NULL
pRB	NULL
was	NULL
strongly	NULL
expressed	NULL
at	NULL
115	NULL
kD	NULL
in	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Culture	NULL
with	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
led	NULL
to	NULL
downregulation	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
in	NULL
MM	NULL
patient	NULL
cells	NULL
and	NULL
MM	NULL
cell	NULL
lines	NULL
in	NULL
several	NULL
patterns	NULL
.	NULL

In	NULL
XG-1	NULL
,	NULL
U-266	NULL
,	NULL
OCI-My-5	NULL
,	NULL
and	NULL
patient	NULL
!	NULL

MM	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
CMK	NULL
leukemia	NULL
cells	NULL
,	NULL
dephosphorylated	NULL
pRB	NULL
expression	NULL
declined	NULL
in	NULL
lysates	NULL
from	NULL
cells	NULL
cultured	NULL
with	NULL
IL-6	NULL
for	NULL
30	NULL
and	NULL
240	NULL
minutes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
dephosphorylated	NULL
pRB	NULL
expression	NULL
persisted	NULL
at	NULL
30	NULL
minutes	NULL
and	NULL
declined	NULL
only	NULL
at	NULL
240	NULL
minutes	NULL
in	NULL
cell	NULL
lysates	NULL
of	NULL
U-1958	NULL
and	NULL
patient	NULL
2	NULL
MM	NULL
cells	NULL
cultured	NULL
with	NULL
IL-6	NULL
.	NULL

In	NULL
ARH-77	NULL
,	NULL
RPMI-8226	NULL
,	NULL
and	NULL
IM-9	NULL
MM	NULL
cells	NULL
,	NULL
there	NULL
were	NULL
several	NULL
pRB	NULL
bands	NULL
in	NULL
addition	NULL
to	NULL
phosphorylated	NULL
pRB	NULL
at	NULL
115	NULL
kD	NULL
;	NULL
IL-6	NULL
increased	NULL
phosphorylated	NULL
pRB	NULL
and	NULL
decreased	NULL
dephosphorylated	NULL
pRB	NULL
in	NULL
these	NULL
MM	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
pRB	NULL
in	NULL
JKB	NULL
ALL	NULL
cells	NULL
was	NULL
constitutively	NULL
phosphorylated	NULL
and	NULL
unaffected	NULL
by	NULL
culture	NULL
with	NULL
IL-6	NULL
.	NULL

pRB	NULL
expression	NULL
in	NULL
splenic	NULL
B	NULL
cells	NULL
cultured	NULL
in	NULL
media	NULL
or	NULL
triggered	NULL
with	NULL
CD4O0L	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
MM	NULL
cells	NULL
.	NULL

pRB	NULL
in	NULL
splenic	NULL
B	NULL
cells	NULL
was	NULL
predominantly	NULL
in	NULL
the	NULL
dephosphorylated	NULL
form	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
MM	NULL
cells	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
,	NULL
treatment	NULL
with	NULL
IL-6	NULL
did	NULL
not	NULL
alter	NULL
pRB	NULL
phosphorylation	NULL
state	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

CD4OL	NULL
upregulated	NULL
phosphorylated	NULL
pRB	NULL
at	NULL
115	NULL
kD	NULL
and	NULL
downregulated	NULL
dephosphorylated	NULL
pRB	NULL
at	NULL
105	NULL
kD	NULL
in	NULL
splenic	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
;	NULL
IL-6	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
pRB	NULL
phosphorylation	NULL
in	NULL
CD4OL-treated	NULL
B	NULL
cells	NULL
.	NULL

Effects	NULL
of	NULL
IL-6	NULL
on	NULL
binding	NULL
of	NULL
pRB	NULL
to	NULL
E2F	NULL
protein	NULL
in	NULL
MM	NULL
patient	NULL
cells/MM	NULL
cell	NULL
lines	NULL
.	NULL

Because	NULL
dephosphorylated	NULL
pRB	NULL
directly	NULL
binds	NULL
E2F	NULL
and	NULL
the	NULL
complex	NULL
of	NULL
pRB	NULL
and	NULL
EZF	NULL
binds	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
gene	NULL
promotors	NULL
resulting	NULL
in	NULL
growth	NULL
arrest	NULL
,	NULL
we	NULL
determined	NULL
whether	NULL
downregulation	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
in	NULL
MM	NULL
cells	NULL
correlates	NULL
with	NULL
pRB	NULL
decreased	NULL
binding	NULL
to	NULL
EZF	NULL
protein	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

Lysates	NULL
of	NULL
patient	NULL
1	NULL
MM	NULL
cells	NULL
starved	NULL
of	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
were	NULL
immunoprecipitated	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2222	NULL
URASHIMA	NULL
ET	NULL
AL	NULL
XG-1	NULL
U-266	NULL
OCI-MyS5	NULL
Patient	NULL
1	NULL
A	NULL
IL-6	NULL
IL-6	NULL
IL-6	NULL
IL-6	NULL
min	NULL
O0	NULL
30	NULL
240	NULL
0	NULL
30	NULL
240	NULL
0	NULL
30	NULL
240	NULL
_	NULL
0	NULL
30	NULL
240	NULL
Phosphorylated	NULL
?	NULL

«	NULL
1	NULL
17kd	NULL
pRB	NULL
*	NULL
%	NULL
cad	NULL
Pal	NULL
*I	NULL
|	NULL
``	NULL
3	NULL
.	NULL

«	NULL
«	NULL
890kd	NULL
Dephosphorylated	NULL
pRB	NULL
CMK	NULL
U-1958	NULL
Patient	NULL
2	NULL
ARH-77	NULL
IL-6	NULL
IL-6	NULL
IL-6	NULL
IL-6	NULL
min	NULL
(	NULL
Q	NULL
30	NULL
240	NULL
0	NULL
30	NULL
240	NULL
O	NULL
30	NULL
240	NULL
0	NULL
30	NULL
240	NULL
Phosphorylated	NULL
ore	NULL
pnory	NULL
117kd	NULL
#	NULL
22	NULL
3	NULL
|	NULL
89kd	NULL
Dephosphorylated	NULL
|	NULL
pRB	NULL
s	NULL
RPMI-8	NULL
226	NULL
IM-9	NULL
JKB	NULL
IL-6	NULL
IL-6	NULL
IL-6	NULL
min	NULL
Q	NULL
30	NULL
240	NULL
O0	NULL
30	NULL
240	NULL
-	NULL
O0	NULL
30	NULL
240	NULL
Phosphorylated	NULL
PBE	NULL
prory	NULL
-	NULL
<	NULL
117kd	NULL
Dephosphorylated	NULL
wap	NULL
pRB	NULL
Fig	NULL
1	NULL
.	NULL

Effects	NULL
of	NULL
IL-6	NULL
on	NULL
phosphorylation	NULL
of	NULL
pRB	NULL
in	NULL
MM	NULL
patient	NULL
cells	NULL
.	NULL

MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
CD4O0L-treated	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
After	NULL
culture	NULL
in	NULL
RPMI-1640	NULL
media	NULL
free	NULL
of	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
,	NULL
patient	NULL
MM	NULL
cells	NULL
,	NULL
MM-derived	NULL
cell	NULL
lines	NULL
(	NULL
XG-1	NULL
,	NULL
U-266	NULL
,	NULL
OCI-My5	NULL
,	NULL
U-1958	NULL
,	NULL
ARH-77	NULL
,	NULL
RPMI-8226	NULL
,	NULL
and	NULL
IM-9	NULL
)	NULL
,	NULL
CMK	NULL
megakaryocytic	NULL
leukemia	NULL
cells	NULL
,	NULL
and	NULL
JKB	NULL
ALL	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10'/sample	NULL
)	NULL
were	NULL
harvested	NULL
before	NULL
and	NULL
at	NULL
30	NULL
minutes	NULL
and	NULL
240	NULL
minutes	NULL
after	NULL
addition	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
.	NULL

with	NULL
anti-pRB	NULL
MoAb	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
same	NULL
MoAb	NULL
and	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
phosphorylated	NULL
pRB	NULL
(	NULL
ppRB	NULL
)	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
(	NULL
dpRB	NULL
)	NULL
.	NULL

Dephosphorylated	NULL
pRB	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
anti-E2F	NULL
polyclonal	NULL
Ab	NULL
in	NULL
XG-1	NULL
,	NULL
U-266	NULL
,	NULL
OCI-My5	NULL
and	NULL
patient	NULL
1	NULL
MM	NULL
cells	NULL
,	NULL
CMK	NULL
megakaryocytic	NULL
cells	NULL
,	NULL
and	NULL
JKB	NULL
ALL	NULL
cells	NULL
after	NULL
serum	NULL
starvation	NULL
for	NULL
48	NULL
hours	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
,	NULL
binding	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
to	NULL
E2F	NULL
was	NULL
downregulated	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
IL-6	NULL
responsive	NULL
CMK	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
IL-6	NULL
nonresponsive	NULL
JKB	NULL
ALL	NULL
cells	NULL
.	NULL

E2F	NULL
expression	NULL
was	NULL
not	NULL
altered	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-6	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

Effect	NULL
of	NULL
RB	NULL
antisense	NULL
and	NULL
sense	NULL
ODNs	NULL
on	NULL
pRB	NULL
expres-sion	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
IL-6	NULL
secretion	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
RB	NULL
antisense	NULL
and	NULL
sense	NULL
ODNs	NULL
on	NULL
pRB	NULL
expres-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-6	NULL
AND	NULL
RB	NULL
IN	NULL
MULTIPLE	NULL
MYELOMA	NULL
2223	NULL
.	NULL

CD4O0L	NULL
B	NULL
Splenic	NULL
_	NULL
Treated	NULL
B	NULL
Cell	NULL
Splenic	NULL
B	NULL
Cells	NULL
Fig	NULL
1	NULL
(	NULL
cont	NULL
'd	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Splenic	NULL
B	NULL
11:6	NULL
Ill-6	NULL
cells	NULL
and	NULL
CD4O0L-treated	NULL
splenic	NULL
&	NULL
B	NULL
cells	NULL
(	NULL
B	NULL
cells	NULL
cultured	NULL
with	NULL
1:4	NULL
min	NULL
0	NULL
30	NULL
240	NULL
0	NULL
30	NULL
240	NULL
soluble	NULL
CD40L	NULL
for	NULL
7	NULL
days	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
media	NULL
free	NULL
of	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
and	NULL
har-	NULL
Phosphorylated	NULL
117kd	NULL
vested	NULL
before	NULL
as	NULL
well	NULL
as	NULL
at	NULL
30	NULL
minutes	NULL
and	NULL
240	NULL
minutes	NULL
after	NULL
pRB	NULL
\-	NULL
'	NULL
|	NULL
a.	NULL
p	NULL
the	NULL
addition	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
.	NULL

y*	NULL
aims	NULL
Cg	NULL
cease	NULL
|	NULL
*	NULL
f	NULL
89kd	NULL
In	NULL
each	NULL
case	NULL
,	NULL
phosphorylation	NULL
of	NULL
a	NULL
pRB	NULL
was	NULL
analyzed	NULL
with	NULL
immuno-	NULL
Dephosphorylated	NULL
precipitation	NULL
followed	NULL
by	NULL
West-	NULL
pRB	NULL
R	NULL
ern	NULL
immunoblotting	NULL
.	NULL

._	NULL
.	NULL

sion	NULL
,	NULL
proliferation	NULL
and	NULL
IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
cells	NULL
from	NULL
three	NULL
patients	NULL
were	NULL
next	NULL
examined	NULL
.	NULL

Both	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
expression	NULL
decreased	NULL
in	NULL
lysates	NULL
of	NULL
cells	NULL
cultured	NULL
for	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RB	NULL
antisense	NULL
ODN	NULL
,	NULL
but	NULL
not	NULL
RB	NULL
sense	NULL
ODN	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Proliferation	NULL
,	NULL
assessed	NULL
by	NULL
'	NULL
H-TdR	NULL
uptake	NULL
,	NULL
was	NULL
significantly	NULL
increased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RB	NULL
antisense	NULL
ODN	NULL
(	NULL
10	NULL
umol/L	NULL
)	NULL
relative	NULL
to	NULL
cultures	NULL
in	NULL
media	NULL
for	NULL
patient	NULL
1	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
patient	NULL
2	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
and	NULL
patient	NULL
3	NULL
(	NULL
P	NULL
<	NULL
.005	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
culture	NULL
with	NULL
RB	NULL
sense	NULL
ODN	NULL
did	NULL
not	NULL
alter	NULL
proliferation	NULL
compared	NULL
with	NULL
cultures	NULL
in	NULL
media	NULL
alone	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
culture	NULL
with	NULL
RB	NULL
sense	NULL
and	NULL
antisense	NULL
ODNs	NULL
on	NULL
IL-6	NULL
secretion	NULL
by	NULL
the	NULL
same	NULL
patient	NULL
MM	NULL
cells	NULL
were	NULL
assayed	NULL
using	NULL
an	NULL
IL-6	NULL
ELISA	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
.	NULL

IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
cells	NULL
in	NULL
media	NULL
was	NULL
0.27	NULL
+	NULL
0.04	NULL
ng/mL	NULL
(	NULL
patient	NULL
1	NULL
)	NULL
,	NULL
0.13	NULL
+	NULL
0.01	NULL
ng/mL	NULL
(	NULL
patient	NULL
2	NULL
)	NULL
,	NULL
and	NULL
0.08	NULL
+	NULL
0.02	NULL
ng/mL	NULL
(	NULL
patient	NULL
3	NULL
)	NULL
.	NULL

When	NULL
MM	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
10	NULL
of	NULL
RB	NULL
antisense	NULL
ODN	NULL
,	NULL
IL-6	NULL
secretion	NULL
increased	NULL
to	NULL
1.21	NULL
+	NULL
0.16	NULL
ng/mL	NULL
(	NULL
patient	NULL
1	NULL
)	NULL
,	NULL
0.72	NULL
+	NULL
0.12	NULL
ng/mL	NULL
(	NULL
patient	NULL
2	NULL
)	NULL
,	NULL
and	NULL
1.33	NULL
+	NULL
0.15	NULL
ng/mL	NULL
(	NULL
patient	NULL
XG-1	NULL
Control	NULL
U-266	NULL
OCI-My5	NULL
Patient	NULL
1	NULL
IL-6	NULL
IL-6	NULL
-+	NULL
3	NULL
)	NULL
,	NULL
significantly	NULL
greater	NULL
than	NULL
by	NULL
MM	NULL
cells	NULL
cultured	NULL
in	NULL
media	NULL
alone	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
for	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
,	NULL
and	NULL
P	NULL
<	NULL
.001	NULL
for	NULL
patient	NULL
3	NULL
)	NULL
or	NULL
by	NULL
MM	NULL
cells	NULL
cultured	NULL
with	NULL
10	NULL
Lmol/L	NULL
RB	NULL
sense	NULL
ODN	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
for	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
and	NULL
P	NULL
<	NULL
.01	NULL
for	NULL
patient	NULL
3	NULL
)	NULL
.	NULL

At	NULL
concentrations	NULL
of	NULL
RB	NULL
antisense	NULL
ODN	NULL
=1	NULL
pmol/L	NULL
,	NULL
no	NULL
significant	NULL
differences	NULL
in	NULL
either	NULL
proliferation	NULL
or	NULL
IL-6	NULL
secretion	NULL
by	NULL
MM	NULL
cells	NULL
were	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
anti-IL-6	NULL
MoAb	NULL
on	NULL
MM	NULL
cell	NULL
proliferation	NULL
triggered	NULL
by	NULL
RB	NULL
antisense	NULL
ODN	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
whether	NULL
the	NULL
increased	NULL
proliferation	NULL
of	NULL
MM	NULL
cells	NULL
observed	NULL
in	NULL
RB	NULL
antisense	NULL
cultures	NULL
was	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
mediated	NULL
by	NULL
IL-6	NULL
.	NULL

IL-6	NULL
responsive	NULL
patient	NULL
MM	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
4	NULL
days	NULL
with	NULL
RB	NULL
antisense	NULL
or	NULL
RB	NULL
sense	NULL
ODN	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
neutralizing	NULL
anti-IL-6	NULL
MoAb	NULL
.	NULL

IL-6	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
markedly	NULL
increased	NULL
proliferation	NULL
of	NULL
patient	NULL
MM	NULL
cells	NULL
:	NULL
SI	NULL
32.2	NULL
at	NULL
day	NULL
4	NULL
in	NULL
10	NULL
%	NULL
FBS	NULL
RPMI-1640	NULL
media	NULL
,	NULL
a	NULL
response	NULL
that	NULL
was	NULL
significantly	NULL
blocked	NULL
(	NULL
73	NULL
%	NULL
reduction	NULL
,	NULL
P	NULL
<	NULL
.001	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
by	NULL
neutralizing	NULL
anti-IL-6	NULL
MoAb	NULL
(	NULL
10	NULL
ug/mL	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
control	NULL
MoAb	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

During	NULL
the	NULL
first	NULL
3	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
there	NULL
IL-6	NULL
--	NULL
-	NULL
[	NULL
--	NULL
=	NULL
wos	NULL
H	NULL
o	NULL
H	NULL
Fig	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
IL-6	NULL
on	NULL
binding	NULL
of	NULL
pRB	NULL
to	NULL
E2F	NULL
protein	NULL
in	NULL
MM	NULL
patient	NULL
cells/	NULL
MM	NULL
cell	NULL
lines	NULL
.	NULL

After	NULL
culture	NULL
in	NULL
RPMI-1640	NULL
media	NULL
free	NULL
of	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
,	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
XG-1	NULL
,	NULL
U-266	NULL
,	NULL
and	NULL
OCI-My5	NULL
)	NULL
,	NULL
patient	NULL
MM	NULL
cells	NULL
,	NULL
CMK	NULL
megakaryocytic	NULL
leukemia	NULL
cells	NULL
,	NULL
and	NULL
JKB	NULL
ALL	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10'/sample	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-E2F	NULL
polyclonal	NULL
Ab	NULL
,	NULL
immunoblotted	NULL
with	NULL
anti-RB	NULL
MoAb	NULL
or	NULL
anti-E2F	NULL
MoAb	NULL
,	NULL
and	NULL
detected	NULL
using	NULL
an	NULL
ECL	NULL
system	NULL
.	NULL

Lysate	NULL
of	NULL
patient	NULL
1	NULL
MM	NULL
cells	NULL
starved	NULL
of	NULL
FBS	NULL
for	NULL
48	NULL
hours	NULL
,	NULL
immunoprecipitated	NULL
with	NULL
anti-pRB	NULL
MoAb	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
same	NULL
MoAb	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
phosphorylated	NULL
pRB	NULL
(	NULL
ppRB	NULL
)	NULL
and	NULL
dephosphorylated	NULL
pRB	NULL
(	NULL
dpRB	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2224	NULL
were	NULL
no	NULL
significant	NULL
differences	NULL
in	NULL
proliferation	NULL
of	NULL
patient	NULL
MM	NULL
cells	NULL
cultured	NULL
with	NULL
RB	NULL
sense	NULL
or	NULL
RB	NULL
antisense	NULL
ODNs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
anti-IL-6	NULL
MoAb	NULL
(	NULL
Fig	NULL
4B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
at	NULL
day	NULL
4	NULL
of	NULL
culture	NULL
,	NULL
RB	NULL
antisense	NULL
ODN	NULL
significantly	NULL
increased	NULL
MM	NULL
cell	NULL
proliferation	NULL
,	NULL
compared	NULL
with	NULL
cultures	NULL
in	NULL
media	NULL
alone	NULL
(	NULL
12.7-fold	NULL
,	NULL
P	NULL
<	NULL
.001	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
or	NULL
with	NULL
RB	NULL
sense	NULL
ODN	NULL
(	NULL
14.1-fold	NULL
,	NULL
P	NULL
<	NULL
.001	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

Neutralizing	NULL
anti-IL-6	NULL
MoAb	NULL
,	NULL
but	NULL
not	NULL
control	NULL
MoAb	NULL
,	NULL
partially	NULL
inhibited	NULL
proliferation	NULL
triggered	NULL
by	NULL
RB	NULL
antisense	NULL
ODN	NULL
(	NULL
42.2	NULL
%	NULL
reduction	NULL
,	NULL
P	NULL
<	NULL
02	NULL
,	NULL
n	NULL
=	NULL
3	NULL
)	NULL
.	NULL

DISCUSSION	NULL
IL-6	NULL
is	NULL
known	NULL
to	NULL
be	NULL
both	NULL
an	NULL
autocrine	NULL
and	NULL
paracrine	NULL
growth	NULL
factor	NULL
,	NULL
as	NULL
well	NULL
as	NULL
an	NULL
antiapoptotic	NULL
factor	NULL
,	NULL
for	NULL
MM	NULL
cells	NULL
.	NULL

Recent	NULL
studies	NULL
that	NULL
show	NULL
that	NULL
retroviruses	NULL
containing	NULL
mye	NULL
and	NULL
raf	NULL
oncogenes	NULL
induce	NULL
plasmacytomas	NULL
in	NULL
pristane-injected	NULL
wild	NULL
type	NULL
,	NULL
but	NULL
not	NULL
in	NULL
IL-6	NULL
knock	NULL
out	NULL
,	NULL
mice	NULL
``	NULL
support	NULL
this	NULL
central	NULL
role	NULL
of	NULL
IL-6	NULL
in	NULL
the	NULL
growth	NULL
and	NULL
development	NULL
of	NULL
plasma	NULL
cell	NULL
tumors	NULL
.	NULL

However	NULL
,	NULL
plasmacytosis	NULL
without	NULL
monoclonal	NULL
plamacytomas	NULL
develops	NULL
in	NULL
IL-6	NULL
transgenic	NULL
B6	NULL
mice	NULL
,	NULL
``	NULL
°	NULL
whereas	NULL
monoclonal	NULL
transplantable	NULL
plamacytomas	NULL
occur	NULL
in	NULL
IL-6	NULL
transgenic	NULL
BALB/c	NULL
mice	NULL
,	NULL
demonstrating	NULL
the	NULL
import	NULL
of	NULL
genetic	NULL
background	NULL
on	NULL
the	NULL
biologic	NULL
sequelae	NULL
of	NULL
excess	NULL
IL-6	NULL
.	NULL
``	NULL

Moreover	NULL
,	NULL
in	NULL
man	NULL
,	NULL
excess	NULL
production	NULL
of	NULL
IL-6	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
diseases	NULL
other	NULL
than	NULL
plamacytomas	NULL
or	NULL
MM	NULL
,	NULL
ie	NULL
,	NULL
cardiac	NULL
myxomas	NULL
,	NULL
autoimmune	NULL
conditions	NULL
,	NULL
and	NULL
Castleman	NULL
's	NULL
disease	NULL
,	NULL
'	NULL
further	NULL
suggesting	NULL
the	NULL
importance	NULL
of	NULL
other	NULL
genetic	NULL
factors	NULL
.	NULL

In	NULL
human	NULL
MM	NULL
,	NULL
IL-6	NULL
triggers	NULL
proliferation	NULL
of	NULL
tumor	NULL
cells	NULL
and	NULL
is	NULL
,	NULL
therefore	NULL
,	NULL
a	NULL
growth	NULL
factor	NULL
;	NULL
however	NULL
,	NULL
not	NULL
all	NULL
MM	NULL
cells	NULL
and	NULL
MM	NULL
cell	NULL
lines	NULL
that	NULL
bear	NULL
IL-6	NULL
receptors	NULL
respond	NULL
to	NULL
exogenous	NULL
IL-6	NULL
,	NULL
and	NULL
some	NULL
can	NULL
grow	NULL
independently	NULL
of	NULL
IL-6	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shed	NULL
insight	NULL
into	NULL
potential	NULL
differences	NULL
in	NULL
IL-6	NULL
signaling	NULL
cascades	NULL
in	NULL
MM	NULL
cells	NULL
that	NULL
proliferate	NULL
and	NULL
those	NULL
that	NULL
do	NULL
not	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
.	NULL

For	NULL
example	NULL
,	NULL
our	NULL
recent	NULL
studies	NULL
suggest	NULL
that	NULL
IL-6	NULL
triggers	NULL
activation	NULL
of	NULL
the	NULL
STAT	NULL
3	NULL
homodimer	NULL
and	NULL
STAT1-STAT3	NULL
heterodimer	NULL
cascades	NULL
without	NULL
altering	NULL
DNA	NULL
synthesis	NULL
of	NULL
MM	NULL
cells	NULL
,	NULL
whereas	NULL
IL-6	NULL
triggers	NULL
MM	NULL
cell	NULL
growth	NULL
via	NULL
the	NULL
Ras	NULL
dependent	NULL
MAPK	NULL
cas-cade	NULL
.	NULL
``	NULL

Clearly	NULL
differences	NULL
in	NULL
IL-6	NULL
signal	NULL
transduction	NULL
cascades	NULL
may	NULL
underly	NULL
the	NULL
triggering	NULL
by	NULL
IL-6	NULL
of	NULL
growth	NULL
of	NULL
MM	NULL
cells	NULL
versus	NULL
differentiation	NULL
of	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
growth	NULL
of	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
tumor	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
set	NULL
out	NULL
to	NULL
delineate	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
RB	NULL
cell	NULL
cycle	NULL
regulatory	NULL
protein	NULL
,	NULL
as	NULL
abnormalities	NULL
of	NULL
Fig	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
RB	NULL
antisense	NULL
and	NULL
sense	NULL
ODNs	NULL
on	NULL
pRB	NULL
expression	NULL
proliferation	NULL
and	NULL
IL-6	NULL
secretion	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Patient	NULL
MM	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10'/sample	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
4	NULL
days	NULL
in	NULL
10	NULL
%	NULL
FBS	NULL
RPMI-1640	NULL
media	NULL
alone	NULL
or	NULL
with	NULL
10	NULL
mmol/L	NULL
RB	NULL
sense	NULL
ODN	NULL
or	NULL
RB	NULL
antisense	NULL
ODN	NULL
;	NULL
ODNs	NULL
were	NULL
replenished	NULL
daily	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-pRB	NULL
MoAb	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
same	NULL
MoAb	NULL
.	NULL

Patient	NULL
MM	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/mL	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
10	NULL
%	NULL
FBS	NULL
RPMI-1640	NULL
media	NULL
alone	NULL
(	NULL
M	NULL
)	NULL
or	NULL
with	NULL
10	NULL
mol/L	NULL
RB	NULL
sense	NULL
ODN	NULL
(	NULL
2	NULL
)	NULL
or	NULL
10	NULL
pmol/L	NULL
RB	NULL
antisense	NULL
ODN	NULL
(	NULL
M	NULL
)	NULL
;	NULL
ODNs	NULL
were	NULL
replenished	NULL
daily	NULL
.	NULL

(	NULL
B	NULL
)	NULL
°H-TdR	NULL
uptake	NULL
was	NULL
measured	NULL
during	NULL
the	NULL
last	NULL
18	NULL
hours	NULL
of	NULL
4-day	NULL
cultures	NULL
.	NULL

(	NULL
C	NULL
)	NULL
IL-6	NULL
concentration	NULL
(	NULL
ng/mL	NULL
)	NULL
in	NULL
supernatants	NULL
of	NULL
day	NULL
4	NULL
cultures	NULL
were	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

Data	NULL
shown	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
from	NULL
four	NULL
independent	NULL
experiments	NULL
and	NULL
were	NULL
compared	NULL
using	NULL
two	NULL
sample	NULL
t	NULL
tests	NULL
.	NULL

URASHIMA	NULL
ET	NULL
AL	NULL
pRB	NULL
or	NULL
mutations	NULL
of	NULL
RB	NULL
gene	NULL
have	NULL
been	NULL
noted	NULL
in	NULL
up	NULL
to	NULL
70	NULL
%	NULL
to	NULL
80	NULL
%	NULL
of	NULL
MM	NULL
patients	NULL
and	NULL
derived	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
Specifically	NULL
,	NULL
mutations	NULL
of	NULL
the	NULL
RB	NULL
tumor	NULL
suppressor	NULL
gene	NULL
have	NULL
been	NULL
frequently	NULL
observed	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
the	NULL
XG-1	NULL
,	NULL
RPMI-8226	NULL
,	NULL
U-266	NULL
,	NULL
and	NULL
IM-9	NULL
MM	NULL
derived	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
A	NULL
Phosphorylated	NULL
pRB	NULL
Dephosphorylated	NULL
pRB	NULL
8000	NULL
B	NULL
``	NULL
(	NULL
cpm	NULL
)	NULL
3H-TdR	NULL
-	NULL
Uptake	NULL
Patient	NULL
1	NULL
Patient	NULL
2	NULL
Patient	NULL
3	NULL
2.0	NULL
7	NULL
O	NULL
(	NULL
ng/ml	NULL
)	NULL
Secretion	NULL
IL-6	NULL
Patient	NULL
1	NULL
Patient	NULL
2	NULL
Patient	NULL
3	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-6	NULL
AND	NULL
RB	NULL
IN	NULL
MULTIPLE	NULL
MYELOMA	NULL
40000	NULL
A	NULL
``	NULL
~	NULL
|	NULL
E	NULL
-	NULL
30000	NULL
[	NULL
-	NULL
``	NULL
IJ	NULL
4	NULL
``	NULL
3	NULL
#	NULL
,	NULL
-	NULL
20000	NULL
--	NULL
E	NULL
O	NULL
10000	NULL
7	NULL
&	NULL
a	NULL
0	NULL
U	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
s	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Days	NULL
in	NULL
-	NULL
Culture	NULL
2225	NULL
8000	NULL
7	NULL
B	NULL
5	NULL
:	NULL
6000	NULL
7	NULL
4	NULL
c	NULL
5	NULL
.	NULL

-	NULL
4000	NULL
-=-	NULL
&	NULL
wis	NULL
2000	NULL
&	NULL
0	NULL
U	NULL
T	NULL
1	NULL
*	NULL
1	NULL
U	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Days	NULL
in	NULL
Culture	NULL
Fig	NULL
4	NULL
.	NULL

|	NULL
Effect	NULL
of	NULL
anti-IL-6	NULL
MoAb	NULL
on	NULL
MM	NULL
cell	NULL
proliferation	NULL
triggered	NULL
by	NULL
RB	NULL
antisense	NULL
ODN	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Patient	NULL
MM	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/mL	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
media	NULL
alone	NULL
(	NULL
0	NULL
)	NULL
;	NULL
with	NULL
IL-6	NULL
{	NULL
10	NULL
ng/ml	NULL
)	NULL
(	NULL
@	NULL
)	NULL
;	NULL
with	NULL
IL-6	NULL
plus	NULL
control	NULL
MoAb	NULL
(	NULL
U	NULL
)	NULL
;	NULL
and	NULL
with	NULL
IL-6	NULL
and	NULL
anti-IL-6	NULL
MoAb	NULL
(	NULL
M	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Patient	NULL
MM	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
media	NULL
alone	NULL
(	NULL
O	NULL
)	NULL
;	NULL
with	NULL
RB	NULL
antisense	NULL
ODN	NULL
(	NULL
10	NULL
pmol/L	NULL
)	NULL
(	NULL
@	NULL
)	NULL
;	NULL
with	NULL
RB	NULL
sense	NULL
ODN	NULL
{	NULL
10	NULL
gmol/L	NULL
)	NULL
(	NULL
D	NULL
)	NULL
;	NULL
with	NULL
RB	NULL
antisense	NULL
ODN	NULL
(	NULL
10	NULL
umol/	NULL
L	NULL
}	NULL
and	NULL
anti-lL-6	NULL
MoAb	NULL
(	NULL
M	NULL
)	NULL
;	NULL
as	NULL
well	NULL
as	NULL
with	NULL
RB	NULL
antisense	NULL
ODN	NULL
and	NULL
control	NULL
MoAb	NULL
(	NULL
A	NULL
)	NULL
.	NULL

in	NULL
all	NULL
cases	NULL
,	NULL
DNA	NULL
synthesis	NULL
was	NULL
measured	NULL
using	NULL
°H-TdR	NULL
uptake	NULL
during	NULL
the	NULL
last	NULL
18	NULL
hours	NULL
of	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
96	NULL
,	NULL
and	NULL
120-hour	NULL
cultures	NULL
.	NULL

ODNs	NULL
and	NULL
MoAbs	NULL
were	NULL
replenished	NULL
daily	NULL
.	NULL

Data	NULL
shown	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
and	NULL
were	NULL
compared	NULL
using	NULL
two	NULL
sample	NULL
t	NULL
tests	NULL
.	NULL

These	NULL
are	NULL
monoalleic	NULL
deletions	NULL
and	NULL
pRB	NULL
,	NULL
the	NULL
product	NULL
of	NULL
RB	NULL
gene	NULL
,	NULL
can	NULL
be	NULL
detected	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
bialleic	NULL
deletion	NULL
of	NULL
RB	NULL
gene	NULL
and	NULL
absence	NULL
of	NULL
pRB	NULL
was	NULL
reported	NULL
in	NULL
U-266	NULL
MM	NULL
cells	NULL
,	NULL
which	NULL
both	NULL
produce	NULL
and	NULL
respond	NULL
to	NULL
IL-6	NULL
(	NULL
autocrine	NULL
growth	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
parental	NULL
U-266	NULL
cells	NULL
,	NULL
which	NULL
respond	NULL
but	NULL
do	NULL
not	NULL
produce	NULL
IL-6	NULL
(	NULL
paracrine	NULL
growth	NULL
)	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Interestingly	NULL
either	NULL
partial	NULL
or	NULL
complete	NULL
deletions	NULL
of	NULL
chromosome	NULL
13	NULL
,	NULL
on	NULL
which	NULL
RB	NULL
gene	NULL
is	NULL
located	NULL
,	NULL
or	NULL
abnormalities	NULL
involving	NULL
11q	NULL
,	NULL
on	NULL
which	NULL
bel-1	NULL
is	NULL
located	NULL
,	NULL
are	NULL
frequent	NULL
and	NULL
associated	NULL
with	NULL
poor	NULL
prognosis	NULL
in	NULL
MM	NULL
.	NULL

**	NULL
Moreover	NULL
,	NULL
cyclin	NULL
D1	NULL
,	NULL
which	NULL
can	NULL
trigger	NULL
phosphorylation	NULL
of	NULL
pRB	NULL
,	NULL
is	NULL
located	NULL
on	NULL
the	NULL
110	NULL
kb	NULL
telomeric	NULL
of	NULL
the	NULL
bel-1	NULL
major	NULL
translocation	NULL
cluster	NULL
region	NULL
;	NULL
its	NULL
overex-pression	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
various	NULL
kinds	NULL
of	NULL
cancers	NULL
with	NULL
11q	NULL
abnormalites	NULL
,	NULL
such	NULL
as	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
.	NULL
``	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
pRB	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
expressed	NULL
both	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
and	NULL
MM-derived	NULL
cell	NULL
lines	NULL
,	NULL
primarily	NULL
in	NULL
its	NULL
phosphorylated	NULL
form	NULL
.	NULL

Although	NULL
serum	NULL
starvation	NULL
for	NULL
72	NULL
hours	NULL
both	NULL
decreased	NULL
growth	NULL
and	NULL
increased	NULL
expression	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
,	NULL
phosphorylated	NULL
pRB	NULL
persisted	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
normal	NULL
splenic	NULL
B	NULL
cells	NULL
in	NULL
which	NULL
pRB	NULL
is	NULL
dephos-phorylated	NULL
,	NULL
with	NULL
complete	NULL
absence	NULL
of	NULL
phosphorylated	NULL
pRB	NULL
.	NULL

Complexes	NULL
of	NULL
cyclin	NULL
dependent	NULL
kinase	NULL
(	NULL
CDK	NULL
)	NULL
4	NULL
,	NULL
CDK	NULL
6	NULL
,	NULL
and	NULL
cyclin	NULL
D	NULL
,	NULL
and	NULL
of	NULL
CDK	NULL
2	NULL
and	NULL
cyclin	NULL
E	NULL
regulate	NULL
pRB	NULL
phosphorylation	NULL
``	NULL
;	NULL
however	NULL
,	NULL
the	NULL
mechanism	NULL
whereby	NULL
MM	NULL
cells	NULL
express	NULL
primarily	NULL
phosphorylated	NULL
RB	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
delineated	NULL
.	NULL

In	NULL
our	NULL
study	NULL
,	NULL
pRB	NULL
was	NULL
primarily	NULL
in	NULL
its	NULL
phosphorylated	NULL
form	NULL
in	NULL
MM	NULL
cells/MM-derived	NULL
cell	NULL
lines	NULL
;	NULL
IL-6	NULL
triggered	NULL
tumor	NULL
cell	NULL
proliferation	NULL
and	NULL
downregulation	NULL
of	NULL
dephosphory-	NULL
lated	NULL
pRB	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
dephosphorylated	NULL
pRB	NULL
was	NULL
present	NULL
in	NULL
B	NULL
cells	NULL
;	NULL
CD40L	NULL
induced	NULL
proliferation	NULL
and	NULL
decreased	NULL
dephosphorylated	NULL
pRB	NULL
expression	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
dephosphorylated	NULL
pRB	NULL
,	NULL
rather	NULL
than	NULL
phosphorylated	NULL
pRB	NULL
,	NULL
affects	NULL
B	NULL
and	NULL
MM	NULL
cell	NULL
proliferation	NULL
.	NULL

Dephosphorylated	NULL
pRB	NULL
binds	NULL
E2F	NULL
and	NULL
the	NULL
complex	NULL
induces	NULL
G1	NULL
growth	NULL
arrest	NULL
by	NULL
inhibiting	NULL
transcription	NULL
of	NULL
genes	NULL
regulating	NULL
cell	NULL
replication	NULL
.	NULL
``	NULL

In	NULL
our	NULL
study	NULL
,	NULL
dephosphorylated	NULL
pRB	NULL
bound	NULL
E2F	NULL
protein	NULL
in	NULL
MM	NULL
cells	NULL
under	NULL
conditions	NULL
of	NULL
serum	NULL
starvation	NULL
,	NULL
whereas	NULL
complexes	NULL
of	NULL
pRB-EZF	NULL
decreased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-6	NULL
,	NULL
further	NULL
confirming	NULL
that	NULL
IL-6	NULL
downregulates	NULL
dephosphorylated	NULL
pRB	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
the	NULL
XG-1	NULL
IL-6-dependent	NULL
MM	NULL
cell	NULL
line	NULL
,	NULL
phosphorylated	NULL
pRB	NULL
expression	NULL
persisted	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-6	NULL
,	NULL
although	NULL
dephosphorylated	NULL
pRB	NULL
increased	NULL
and	NULL
growth	NULL
decreased	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
IL-6	NULL
promotes	NULL
MM	NULL
cell	NULL
proliferation	NULL
by	NULL
triggering	NULL
pRB	NULL
phosphorylation	NULL
,	NULL
thereby	NULL
decreasing	NULL
complexes	NULL
of	NULL
dephosphorylated	NULL
pRB	NULL
with	NULL
E2F	NULL
and	NULL
allowing	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
as	NULL
expected	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
of	NULL
mouse	NULL
M1	NULL
leukemia	NULL
cells	NULL
,	NULL
IL-6	NULL
has	NULL
been	NULL
found	NULL
to	NULL
trigger	NULL
dephosphorylation	NULL
of	NULL
pRB	NULL
,	NULL
decrease	NULL
proliferation	NULL
,	NULL
and	NULL
enhance	NULL
differentiation	NULL
,	NULL
further	NULL
demonstrating	NULL
that	NULL
IL-6	NULL
can	NULL
mediate	NULL
biologic	NULL
sequelae	NULL
via	NULL
its	NULL
effects	NULL
on	NULL
RB	NULL
phosphorylation	NULL
state	NULL
.	NULL
``	NULL

''	NULL
Our	NULL
studies	NULL
show	NULL
that	NULL
RB	NULL
antisense	NULL
,	NULL
but	NULL
not	NULL
RB	NULL
sense	NULL
,	NULL
ODN	NULL
induced	NULL
both	NULL
IL-6	NULL
secretion	NULL
and	NULL
proliferation	NULL
in	NULL
patient	NULL
MM	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
setting	NULL
,	NULL
the	NULL
resultant	NULL
reduced	NULL
amounts	NULL
of	NULL
pRB	NULL
,	NULL
including	NULL
dephosphorylated	NULL
pRB	NULL
,	NULL
facilitate	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
as	NULL
mentioned	NULL
above	NULL
.	NULL

However	NULL
,	NULL
a	NULL
component	NULL
of	NULL
the	NULL
proliferation	NULL
noted	NULL
in	NULL
RB	NULL
antisense	NULL
ODN-treated	NULL
MM	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2226	NULL
cells	NULL
in	NULL
our	NULL
study	NULL
was	NULL
blocked	NULL
by	NULL
neutralizing	NULL
MoAb	NULL
to	NULL
IL-6	NULL
.	NULL

These	NULL
studies	NULL
,	NULL
therefore	NULL
,	NULL
suggest	NULL
that	NULL
inactivation	NULL
of	NULL
RB	NULL
can	NULL
contribute	NULL
to	NULL
autocrine	NULL
IL-6-mediated	NULL
growth	NULL
in	NULL
MM	NULL
.	NULL

Although	NULL
not	NULL
directly	NULL
examined	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
increased	NULL
IL-6	NULL
secretion	NULL
induced	NULL
by	NULL
RB	NULL
antisense	NULL
ODN	NULL
treatment	NULL
of	NULL
MM	NULL
cells	NULL
may	NULL
be	NULL
attributed	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
increased	NULL
IL-6	NULL
transcription	NULL
as	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
wild	NULL
type	NULL
,	NULL
but	NULL
not	NULL
mutated	NULL
,	NULL
RB	NULL
can	NULL
repress	NULL
c-fos	NULL
expression	NULL
and	NULL
AP-1	NULL
transcription	NULL
activity	NULL
in	NULL
NIH3T3	NULL
cells	NULL
via	NULL
binding	NULL
to	NULL
a	NULL
cis	NULL
element	NULL
(	NULL
RB	NULL
control	NULL
element	NULL
or	NULL
RCE	NULL
)	NULL
in	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL
``	NULL

RCE	NULL
is	NULL
highly	NULL
analogous	NULL
to	NULL
a	NULL
region	NULL
between	NULL
-126	NULL
and	NULL
-101	NULL
of	NULL
the	NULL
IL-6	NULL
promoter	NULL
,	NULL
and	NULL
pRB	NULL
binds	NULL
directly	NULL
to	NULL
IL-6	NULL
promoter	NULL
and	NULL
represses	NULL
transcription	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
``	NULL
``	NULL
In	NULL
addition	NULL
,	NULL
MacLead	NULL
et	NULL
al	NULL
``	NULL
``	NULL
observed	NULL
nuclear	NULL
proteins	NULL
in	NULL
MM	NULL
cell	NULL
lines	NULL
that	NULL
were	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
NFB	NULL
,	NULL
NF-IL-6	NULL
,	NULL
and	NULL
AP-1	NULL
response	NULL
elements	NULL
and	NULL
whose	NULL
quantity	NULL
positively	NULL
correlated	NULL
with	NULL
IL-6	NULL
production	NULL
by	NULL
these	NULL
cells	NULL
.	NULL

These	NULL
and	NULL
the	NULL
current	NULL
studies	NULL
suggest	NULL
that	NULL
phosphorylated	NULL
(	NULL
inactivated	NULL
)	NULL
pRB	NULL
in	NULL
MM	NULL
,	NULL
due	NULL
to	NULL
its	NULL
inability	NULL
to	NULL
bind	NULL
to	NULL
RCE	NULL
,	NULL
can	NULL
not	NULL
inhibit	NULL
IL-6	NULL
transcription	NULL
;	NULL
therefore	NULL
IL-6	NULL
transcription	NULL
and	NULL
secretion	NULL
may	NULL
occur	NULL
.	NULL

Ongoing	NULL
studies	NULL
are	NULL
delineating	NULL
the	NULL
transcriptional	NULL
versus	NULL
posttran-scriptional	NULL
components	NULL
of	NULL
the	NULL
increases	NULL
in	NULL
IL-6	NULL
secretion	NULL
observed	NULL
in	NULL
the	NULL
present	NULL
report	NULL
.	NULL

Finally	NULL
,	NULL
previous	NULL
reports	NULL
that	NULL
CD40L	NULL
upregulates	NULL
IL-6	NULL
secretion	NULL
and	NULL
phosphorylation	NULL
of	NULL
pRB	NULL
in	NULL
normal	NULL
B	NULL
,	NULL
as	NULL
well	NULL
as	NULL
MM	NULL
cells	NULL
,	NULL
``	NULL
*5©	NULL
are	NULL
also	NULL
consistent	NULL
with	NULL
a	NULL
similar	NULL
mechanism	NULL
.	NULL

Altered	NULL
expression	NULL
of	NULL
pRB	NULL
and	NULL
related	NULL
production	NULL
of	NULL
IL-6	NULL
by	NULL
tumor	NULL
cells	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
in	NULL
30	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
and	NULL
58	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
high	NULL
grade	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
,	NULL
``	NULL
``	NULL
~°	NULL
consistent	NULL
with	NULL
IL-6-mediated	NULL
sequelae	NULL
from	NULL
abnormalities	NULL
in	NULL
pRB	NULL
in	NULL
hematologic	NULL
malignancies	NULL
other	NULL
than	NULL
MM	NULL
.	NULL

Future	NULL
studies	NULL
in	NULL
hematologic	NULL
malignancies	NULL
of	NULL
the	NULL
interactions	NULL
between	NULL
growth	NULL
factors	NULL
and	NULL
abnormalities	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
may	NULL
not	NULL
only	NULL
enhance	NULL
our	NULL
understanding	NULL
of	NULL
tumor	NULL
cell	NULL
growth	NULL
and	NULL
progression	NULL
,	NULL
but	NULL
also	NULL
suggest	NULL
novel	NULL
therapeutic	NULL
strategies	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Kishimoto	NULL
T	NULL
:	NULL
The	NULL
biology	NULL
of	NULL
interleukin-6	NULL
.	NULL

Blood	NULL
74:1	NULL
,	NULL
1989	NULL
2	NULL
.	NULL

Muraguchi	NULL
A	NULL
,	NULL
Kishimoto	NULL
T	NULL
,	NULL
Miki	NULL
Y	NULL
,	NULL
Kuritani	NULL
T	NULL
,	NULL
Kaieda	NULL
T	NULL
,	NULL
Yoshizaki	NULL
K	NULL
,	NULL
Yamamura	NULL
Y	NULL
:	NULL
T	NULL
cell-replacing	NULL
factor	NULL
(	NULL
TFR	NULL
)	NULL
-induced	NULL
IgG	NULL
secretion	NULL
in	NULL
human	NULL
B	NULL
blastoid	NULL
cell	NULL
line	NULL
and	NULL
demonstration	NULL
of	NULL
acceptors	NULL
for	NULL
TRF	NULL
.	NULL

J	NULL
Immunol	NULL
127:412	NULL
,	NULL
1981	NULL
3	NULL
.	NULL

Hirano	NULL
T	NULL
,	NULL
Taga	NULL
T	NULL
,	NULL
Nakano	NULL
N	NULL
,	NULL
Yasukawa	NULL
K	NULL
,	NULL
Kashiwamura	NULL
S	NULL
,	NULL
Shimizu	NULL
K	NULL
,	NULL
Nakajima	NULL
K	NULL
,	NULL
Pyun	NULL
KH	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
Purification	NULL
to	NULL
homogeneity	NULL
and	NULL
characterization	NULL
of	NULL
human	NULL
B	NULL
cell	NULL
differentiation	NULL
factor	NULL
(	NULL
BCDF	NULL
or	NULL
BSFp-2	NULL
)	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
82:5490	NULL
,	NULL
1985	NULL
4	NULL
.	NULL

Kawano	NULL
M	NULL
,	NULL
Hirano	NULL
T	NULL
,	NULL
Matsuda	NULL
T	NULL
,	NULL
Taga	NULL
T	NULL
,	NULL
Horii	NULL
Y	NULL
,	NULL
Iwato	NULL
K	NULL
,	NULL
Asaoku	NULL
H	NULL
,	NULL
Tang	NULL
B	NULL
,	NULL
Tanabe	NULL
O	NULL
,	NULL
Tanaka	NULL
H	NULL
,	NULL
Kuramoto	NULL
A	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
Autocrine	NULL
generation	NULL
and	NULL
requirement	NULL
of	NULL
BSF2/ILG	NULL
for	NULL
human	NULL
multiple	NULL
myeloma	NULL
.	NULL

Nature	NULL
332:83	NULL
,	NULL
1988	NULL
5	NULL
.	NULL

Anderson	NULL
KC	NULL
,	NULL
Jones	NULL
RC	NULL
,	NULL
Morimoto	NULL
C	NULL
,	NULL
Leavitt	NULL
P	NULL
,	NULL
Barut	NULL
B	NULL
:	NULL
Response	NULL
of	NULL
purified	NULL
myeloma	NULL
cells	NULL
to	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
.	NULL

Blood	NULL
73:1915	NULL
,	NULL
1989	NULL
6	NULL
.	NULL

Hata	NULL
H	NULL
,	NULL
Xiao	NULL
H	NULL
,	NULL
Petrucci	NULL
MT	NULL
,	NULL
Woodliff	NULL
J	NULL
,	NULL
Chang	NULL
R	NULL
,	NULL
Epstein	NULL
J	NULL
:	NULL
Interleukin-6	NULL
gene	NULL
expression	NULL
in	NULL
multiple	NULL
myeloma	NULL
:	NULL
A	NULL
characteristic	NULL
of	NULL
immature	NULL
tumor	NULL
cells	NULL
.	NULL

Blood	NULL
81:3357	NULL
,	NULL
1993	NULL
7	NULL
.	NULL

Barut	NULL
B	NULL
,	NULL
Zon	NULL
LI	NULL
,	NULL
Cochran	NULL
MK	NULL
,	NULL
Paul	NULL
SR	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Mohrbacher	NULL
A	NULL
,	NULL
Fingeroth	NULL
J	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
Role	NULL
of	NULL
interleukin	NULL
6	NULL
in	NULL
the	NULL
growth	NULL
of	NULL
myeloma-derived	NULL
cell	NULL
lines	NULL
.	NULL

Leuk	NULL
Res	NULL
16:951	NULL
,	NULL
1992	NULL
URASHIMA	NULL
ET	NULL
AL	NULL
8	NULL
.	NULL

Hitzler	NULL
J	NULL
,	NULL
Martinez-Valdez	NULL
H	NULL
,	NULL
Bergsagel	NULL
D	NULL
,	NULL
Minden	NULL
MD	NULL
:	NULL
Role	NULL
of	NULL
interleukin-6	NULL
in	NULL
the	NULL
proliferation	NULL
of	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
OCI-MY1-7	NULL
established	NULL
from	NULL
patients	NULL
with	NULL
advanced	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Blood	NULL
78:1996	NULL
,	NULL
1991	NULL
9	NULL
.	NULL

Schwab	NULL
M	NULL
,	NULL
Brini	NULL
AT	NULL
,	NULL
Bosco	NULL
MC	NULL
,	NULL
Rubboli	NULL
F	NULL
,	NULL
Egawa	NULL
M	NULL
,	NULL
Zhao	NULL
J	NULL
,	NULL
Princler	NULL
GL	NULL
,	NULL
Kung	NULL
H	NULL
:	NULL
Disruption	NULL
by	NULL
interferon-	NULL
of	NULL
an	NULL
autocrine	NULL
interleukin-6	NULL
growth	NULL
loop	NULL
in	NULL
IL-6-dependent	NULL
U266	NULL
myeloma	NULL
cells	NULL
by	NULL
homologous	NULL
and	NULL
heterogenous	NULL
down-regulation	NULL
of	NULL
IL-6	NULL
receptor	NULL
a-	NULL
and	NULL
B-chains	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
94:2317	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Levy	NULL
Y	NULL
,	NULL
Tsapis	NULL
A	NULL
,	NULL
Brouet	NULL
JC	NULL
:	NULL
Interleukin-6	NULL
antisense	NULL
oligonu-cleotides	NULL
inhibit	NULL
the	NULL
growth	NULL
of	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
88:696	NULL
,	NULL
1991	NULL
11	NULL
.	NULL

Klein	NULL
B	NULL
,	NULL
Zhang	NULL
XZ-G	NULL
,	NULL
Jourdan	NULL
M	NULL
,	NULL
Content	NULL
J	NULL
,	NULL
Houssiau	NULL
F	NULL
,	NULL
Aarden	NULL
L	NULL
,	NULL
Piechaczyk	NULL
M	NULL
,	NULL
Bataille	NULL
R	NULL
:	NULL
Paracrine	NULL
rather	NULL
than	NULL
autocrine	NULL
regulation	NULL
of	NULL
myeloma-cell	NULL
growth	NULL
and	NULL
differentiation	NULL
by	NULL
interleukin-6	NULL
.	NULL

Blood	NULL
73:512	NULL
,	NULL
1989	NULL
12	NULL
.	NULL

Lichtenstein	NULL
A	NULL
,	NULL
Berenson	NULL
J	NULL
,	NULL
Norman	NULL
D	NULL
,	NULL
Chang	NULL
MP	NULL
,	NULL
Carlile	NULL
A	NULL
:	NULL
Production	NULL
of	NULL
cytokines	NULL
by	NULL
bone	NULL
marrow	NULL
cells	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
74:1266	NULL
,	NULL
1989	NULL
13	NULL
.	NULL

Caligaris-Cappio	NULL
F	NULL
,	NULL
Bergui	NULL
L	NULL
,	NULL
Gregoretti	NULL
MG	NULL
,	NULL
Gaidano	NULL
G	NULL
,	NULL
Gaboli	NULL
M	NULL
,	NULL
Schena	NULL
M	NULL
,	NULL
Zallone	NULL
A	NULL
,	NULL
Marchisio	NULL
C	NULL
:	NULL
Role	NULL
of	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
in	NULL
the	NULL
growth	NULL
of	NULL
human	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
77:2688	NULL
,	NULL
1991	NULL
14	NULL
.	NULL

Zhang	NULL
XG	NULL
,	NULL
Gaillard	NULL
JP	NULL
,	NULL
Robillard	NULL
N	NULL
,	NULL
Lu	NULL
AY	NULL
,	NULL
Gu	NULL
ZJ	NULL
,	NULL
Jourdan	NULL
M	NULL
,	NULL
Boiron	NULL
JM	NULL
,	NULL
Bataille	NULL
R	NULL
,	NULL
Klein	NULL
B	NULL
:	NULL
Reproducible	NULL
obtaining	NULL
of	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
as	NULL
a	NULL
model	NULL
for	NULL
tumor	NULL
stem	NULL
cell	NULL
study	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
83:3654	NULL
,	NULL
1994	NULL
15	NULL
.	NULL

Uchiyama	NULL
H	NULL
,	NULL
Barut	NULL
BA	NULL
,	NULL
Mohrbacher	NULL
AF	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
Adhesion	NULL
of	NULL
human	NULL
myeloma-derived	NULL
cell	NULL
lines	NULL
to	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
stimulates	NULL
interleukin-6	NULL
secretion	NULL
.	NULL

Blood	NULL
82:3712	NULL
,	NULL
1993	NULL
16	NULL
.	NULL

Ahsmann	NULL
EJM	NULL
,	NULL
Lokhorst	NULL
HM	NULL
,	NULL
Dekker	NULL
AW	NULL
,	NULL
Bloem	NULL
AC	NULL
:	NULL
Lym-phocyte	NULL
function-associated	NULL
antigen-1	NULL
expression	NULL
on	NULL
plasma	NULL
cells	NULL
correlates	NULL
with	NULL
tumor	NULL
growth	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
79:2068	NULL
,	NULL
1992	NULL
17	NULL
.	NULL

Lichtenstein	NULL
A	NULL
,	NULL
Tu	NULL
Y	NULL
,	NULL
Fady	NULL
C	NULL
,	NULL
Vescio	NULL
R	NULL
,	NULL
Berenson	NULL
J	NULL
:	NULL
Interleukin-6	NULL
inhibits	NULL
apoptosis	NULL
of	NULL
malignant	NULL
plasma	NULL
cells	NULL
.	NULL

Cell	NULL
Immunol	NULL
162:248	NULL
,	NULL
1995	NULL
18	NULL
.	NULL

Kawano	NULL
MM	NULL
,	NULL
Mihara	NULL
K	NULL
,	NULL
Huang	NULL
N	NULL
,	NULL
Tsujimoto	NULL
T	NULL
,	NULL
Kuramoto	NULL
A	NULL
:	NULL
Differentiation	NULL
of	NULL
early	NULL
plasma	NULL
cells	NULL
on	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
requires	NULL
interleukin-6	NULL
for	NULL
escaping	NULL
from	NULL
apoptosis	NULL
.	NULL

Blood	NULL
85:487	NULL
,	NULL
1995	NULL
19	NULL
.	NULL

Hata	NULL
H	NULL
,	NULL
Matsuzaki	NULL
H	NULL
,	NULL
Takeya	NULL
M	NULL
,	NULL
Yoshida	NULL
M	NULL
,	NULL
Sonoki	NULL
T	NULL
,	NULL
Nagasaki	NULL
A	NULL
,	NULL
Kuribayashi	NULL
N	NULL
,	NULL
Kawano	NULL
F	NULL
,	NULL
Takatsuki	NULL
K	NULL
:	NULL
;	NULL
Expression	NULL
of	NULL
Fas/Apo-1	NULL
(	NULL
CD95	NULL
)	NULL
and	NULL
apoptosis	NULL
in	NULL
tumor	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
plasma	NULL
cell	NULL
disorders	NULL
.	NULL

Blood	NULL
86:1939	NULL
,	NULL
1995	NULL
20	NULL
.	NULL

Bataille	NULL
R	NULL
,	NULL
Jourdan	NULL
M	NULL
,	NULL
Zhang	NULL
X-G	NULL
,	NULL
Klein	NULL
B	NULL
:	NULL
Serum	NULL
levels	NULL
of	NULL
interleukin-6	NULL
,	NULL
a	NULL
potent	NULL
myeloma	NULL
cell	NULL
growth	NULL
factor	NULL
,	NULL
as	NULL
a	NULL
reflect	NULL
of	NULL
disease	NULL
severity	NULL
of	NULL
plasma	NULL
cell	NULL
dyscrasias	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
84:2008	NULL
,	NULL
1989	NULL
21	NULL
.	NULL

Ludwig	NULL
H	NULL
,	NULL
Nachbaur	NULL
DM	NULL
,	NULL
Fritz	NULL
E	NULL
,	NULL
Krainer	NULL
M	NULL
,	NULL
Huber	NULL
H	NULL
:	NULL
Interleukin-6	NULL
is	NULL
a	NULL
prognostic	NULL
factor	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
77	NULL
:	NULL
2794	NULL
,	NULL
1991	NULL
22	NULL
.	NULL

Ballester	NULL
OF	NULL
,	NULL
Moscinski	NULL
,	NULL
LC	NULL
,	NULL
Lyman	NULL
GH	NULL
,	NULL
Chaney	NULL
JV	NULL
,	NULL
Saba	NULL
HI	NULL
,	NULL
Spiers	NULL
ASD	NULL
,	NULL
Klein	NULL
B	NULL
:	NULL
High	NULL
levels	NULL
of	NULL
interleukin-6	NULL
are	NULL
associated	NULL
with	NULL
low	NULL
tumor	NULL
burden	NULL
and	NULL
low	NULL
growth	NULL
fraction	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
83	NULL
:	NULL
1903	NULL
,	NULL
1994	NULL
23	NULL
.	NULL

Pelliniemi	NULL
T-T	NULL
,	NULL
Irjala	NULL
K	NULL
,	NULL
Mattila	NULL
K	NULL
,	NULL
Pulkki	NULL
K	NULL
,	NULL
Rajamaki	NULL
A	NULL
,	NULL
Tienhara	NULL
A	NULL
,	NULL
Lakso	NULL
M	NULL
,	NULL
Lahtinen	NULL
R	NULL
:	NULL
Immunoreactive	NULL
interleukin-6	NULL
and	NULL
acute	NULL
phase	NULL
proteins	NULL
as	NULL
prognostic	NULL
factors	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
85	NULL
:	NULL
765	NULL
,	NULL
1995	NULL
24	NULL
.	NULL

Klein	NULL
B	NULL
,	NULL
Wijdenes	NULL
J	NULL
,	NULL
Zhang	NULL
X-G	NULL
,	NULL
Jourdan	NULL
M	NULL
,	NULL
Boiron	NULL
J-M	NULL
,	NULL
Brochier	NULL
J	NULL
,	NULL
Liautard	NULL
J	NULL
,	NULL
Merlin	NULL
M	NULL
,	NULL
Clement	NULL
C	NULL
,	NULL
Morel-Fournier	NULL
B	NULL
,	NULL
Lu	NULL
Z-Y	NULL
,	NULL
Mannoni	NULL
P	NULL
,	NULL
Sany	NULL
J	NULL
,	NULL
Bataille	NULL
R	NULL
:	NULL
Murine	NULL
anti-interleukin-6	NULL
monoclonal	NULL
antibody	NULL
therapy	NULL
for	NULL
a	NULL
patient	NULL
with	NULL
plasma	NULL
cell	NULL
leukemia	NULL
.	NULL

Blood	NULL
78	NULL
:	NULL
1198	NULL
,	NULL
1991	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-6	NULL
AND	NULL
RB	NULL
IN	NULL
MULTIPLE	NULL
MYELOMA	NULL
25	NULL
.	NULL

Hilbert	NULL
DM	NULL
,	NULL
Kopf	NULL
M	NULL
,	NULL
Mock	NULL
BA	NULL
,	NULL
Kohler	NULL
G	NULL
,	NULL
Rudikoff	NULL
S	NULL
:	NULL
Interleukin	NULL
6	NULL
is	NULL
essential	NULL
for	NULL
in	NULL
vivo	NULL
development	NULL
of	NULL
B	NULL
lineage	NULL
neo-plasms	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
182	NULL
;	NULL
243	NULL
,	NULL
1995	NULL
26	NULL
.	NULL

Suematsu	NULL
S	NULL
,	NULL
Matsuda	NULL
T	NULL
,	NULL
Aozasa	NULL
K	NULL
,	NULL
Akira	NULL
S	NULL
,	NULL
Nakao	NULL
N	NULL
,	NULL
Ohno	NULL
S	NULL
,	NULL
Miyazaki	NULL
J	NULL
,	NULL
Yamamura	NULL
K	NULL
,	NULL
Hirano	NULL
T	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
IgG1	NULL
plasmacytosis	NULL
in	NULL
interleukin	NULL
6	NULL
transgenic	NULL
mice	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86	NULL
:	NULL
7547	NULL
,	NULL
1989	NULL
27	NULL
.	NULL

Suematsu	NULL
S	NULL
,	NULL
Matsusaka	NULL
T	NULL
,	NULL
Matsuda	NULL
T	NULL
,	NULL
Ohno	NULL
S	NULL
,	NULL
Miyazaki	NULL
J	NULL
,	NULL
Yamamura	NULL
K	NULL
,	NULL
Hirano	NULL
T	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
Generation	NULL
of	NULL
plasmacytomas	NULL
with	NULL
the	NULL
chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
12	NULL
;	NULL
15	NULL
)	NULL
in	NULL
interleukin-6	NULL
transgenic	NULL
mice	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89	NULL
;	NULL
232	NULL
,	NULL
1994	NULL
28	NULL
.	NULL

DeCaprio	NULL
JA	NULL
,	NULL
Ludlow	NULL
JW	NULL
,	NULL
Lynch	NULL
D	NULL
,	NULL
Furukawa	NULL
Y	NULL
,	NULL
Griffin	NULL
J	NULL
,	NULL
Piwnica-Worms	NULL
H	NULL
,	NULL
Huang	NULL
C-M	NULL
,	NULL
Livingston	NULL
DM	NULL
:	NULL
The	NULL
product	NULL
of	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
has	NULL
properties	NULL
of	NULL
a	NULL
cell	NULL
cycle	NULL
regulatory	NULL
element	NULL
.	NULL

Cell	NULL
58	NULL
:	NULL
1085	NULL
,	NULL
1989	NULL
29	NULL
.	NULL

Mittnacht	NULL
S	NULL
,	NULL
Weinberg	NULL
RA	NULL
:	NULL
G1/S	NULL
phosphorylation	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
altered	NULL
affinity	NULL
for	NULL
the	NULL
nuclear	NULL
compartment	NULL
.	NULL

Cell	NULL
65	NULL
:	NULL
381	NULL
,	NULL
1991	NULL
30	NULL
.	NULL

Weinberg	NULL
RA	NULL
:	NULL
The	NULL
retinoblastoma	NULL
protein	NULL
and	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

Cell	NULL
81	NULL
:	NULL
323	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

Chellappan	NULL
SP	NULL
,	NULL
Hiebert	NULL
S	NULL
,	NULL
Mudryi	NULL
M	NULL
,	NULL
Horowitz	NULL
JM	NULL
,	NULL
Nevins	NULL
JR	NULL
:	NULL
The	NULL
E2F	NULL
transcription	NULL
factor	NULL
is	NULL
a	NULL
cellular	NULL
target	NULL
for	NULL
the	NULL
RB	NULL
protein	NULL
.	NULL

Cell	NULL
65	NULL
:	NULL
1053	NULL
,	NULL
1991	NULL
32	NULL
.	NULL

LaThangue	NULL
NB	NULL
;	NULL
DRTFI/E2F	NULL
:	NULL
An	NULL
expanding	NULL
family	NULL
of	NULL
hetero-dimeric	NULL
transcription	NULL
factors	NULL
implicated	NULL
in	NULL
cell-cycle	NULL
control	NULL
.	NULL

Trends	NULL
Biochem	NULL
Sci	NULL
19:108	NULL
,	NULL
1994	NULL
33	NULL
.	NULL

Dao	NULL
DD	NULL
,	NULL
Sawyer	NULL
JR	NULL
,	NULL
Epstein	NULL
J	NULL
,	NULL
Hoover	NULL
RG	NULL
,	NULL
Barlogie	NULL
B	NULL
,	NULL
Tricot	NULL
G	NULL
:	NULL
Deletion	NULL
of	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Leukemia	NULL
8:1280	NULL
,	NULL
1994	NULL
34	NULL
.	NULL

Corradini	NULL
P	NULL
,	NULL
Inghirami	NULL
G	NULL
,	NULL
Astolfi	NULL
M	NULL
,	NULL
Ladetto	NULL
M	NULL
,	NULL
Voena	NULL
C	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Gu	NULL
W	NULL
,	NULL
Nilsson	NULL
K	NULL
,	NULL
Knowles	NULL
DM	NULL
,	NULL
Boccadoro	NULL
M	NULL
,	NULL
Pileri	NULL
A	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
:	NULL
Inactivation	NULL
of	NULL
tumor	NULL
suppressor	NULL
genes	NULL
,	NULL
p53	NULL
and	NULL
Rb1	NULL
,	NULL
in	NULL
plasma	NULL
cell	NULL
dyscrasias	NULL
.	NULL

Leukemia	NULL
8:758	NULL
,	NULL
1994	NULL
35	NULL
.	NULL

Juge-Morineau	NULL
N	NULL
,	NULL
Mellerin	NULL
M-P	NULL
,	NULL
Francois	NULL
S	NULL
,	NULL
Rapp	NULL
M-J	NULL
,	NULL
Ha-rousseau	NULL
J-L	NULL
,	NULL
Amiot	NULL
M	NULL
,	NULL
Bataille	NULL
R	NULL
:	NULL
High	NULL
incidence	NULL
of	NULL
deletions	NULL
but	NULL
infrequent	NULL
inactivation	NULL
of	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
in	NULL
human	NULL
myeloma	NULL
cells	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
91:664	NULL
,	NULL
1995	NULL
36	NULL
.	NULL

Urashima	NULL
M	NULL
,	NULL
Ogata	NULL
A	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Hatziyanni	NULL
M	NULL
,	NULL
Vidriales	NULL
MB	NULL
,	NULL
Dedera	NULL
DA	NULL
,	NULL
Schlossman	NULL
RL	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
Transforming	NULL
growth	NULL
factor	NULL
31	NULL
:	NULL
Differential	NULL
effects	NULL
on	NULL
multiple	NULL
myeloma	NULL
versus	NULL
normal	NULL
B	NULL
cells	NULL
.	NULL

Blood	NULL
87:1928	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Jernberg	NULL
H	NULL
,	NULL
Nilsson	NULL
K	NULL
,	NULL
Zech	NULL
L	NULL
,	NULL
Lutz	NULL
D	NULL
,	NULL
Nowotny	NULL
H	NULL
,	NULL
Scheirer	NULL
W	NULL
:	NULL
Establishment	NULL
and	NULL
phenotypic	NULL
characterization	NULL
of	NULL
three	NULL
new	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
(	NULL
U-1957	NULL
,	NULL
U-1958	NULL
,	NULL
and	NULL
U-1996	NULL
)	NULL
.	NULL

Blood	NULL
69:1605	NULL
,	NULL
1987	NULL
38	NULL
.	NULL

Urashima	NULL
M	NULL
,	NULL
Hasegawa	NULL
N	NULL
,	NULL
Kamijo	NULL
M	NULL
,	NULL
Shishikura	NULL
A	NULL
,	NULL
Kato	NULL
Y	NULL
,	NULL
Hoshi	NULL
Y	NULL
,	NULL
Akatsuka	NULL
JI	NULL
,	NULL
Maekawa	NULL
K	NULL
:	NULL
Establishment	NULL
of	NULL
a	NULL
human	NULL
pro-B	NULL
cell	NULL
line	NULL
(	NULL
JKB-1	NULL
)	NULL
and	NULL
its	NULL
differentiation	NULL
on	NULL
preestablished	NULL
bone	NULL
marrow	NULL
stromal	NULL
cell	NULL
layer	NULL
.	NULL

Am	NULL
J	NULL
Hematol	NULL
46:112	NULL
,	NULL
1994	NULL
39	NULL
.	NULL

Sato	NULL
T	NULL
,	NULL
Fuse	NULL
A	NULL
,	NULL
Eguchi	NULL
M	NULL
,	NULL
Hayashi	NULL
Y	NULL
,	NULL
Ryo	NULL
R	NULL
,	NULL
Adachi	NULL
M	NULL
,	NULL
Kishimoto	NULL
Y	NULL
,	NULL
Teramura	NULL
M	NULL
,	NULL
Mizoguchi	NULL
H	NULL
,	NULL
Shima	NULL
Y	NULL
:	NULL
Establishment	NULL
of	NULL
a	NULL
human	NULL
leukaemic	NULL
cell	NULL
line	NULL
(	NULL
CMK	NULL
)	NULL
with	NULL
megakaryocytic	NULL
characteristics	NULL
from	NULL
a	NULL
Down	NULL
's	NULL
syndrome	NULL
patient	NULL
with	NULL
acute	NULL
megakaryocytic	NULL
leukemia	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
72:184	NULL
,	NULL
1989	NULL
40	NULL
.	NULL

Fuse	NULL
A	NULL
,	NULL
Kakuda	NULL
T	NULL
,	NULL
Shima	NULL
Y	NULL
,	NULL
Van	NULL
Damme	NULL
J	NULL
,	NULL
Billiau	NULL
A	NULL
,	NULL
Sato	NULL
T	NULL
:	NULL
Interleukin	NULL
6	NULL
,	NULL
a	NULL
possible	NULL
autocrine	NULL
growth	NULL
and	NULL
differentiation	NULL
factor	NULL
for	NULL
the	NULL
human	NULL
megakaryocytic	NULL
cell	NULL
line	NULL
,	NULL
CMK	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
77:32	NULL
,	NULL
1991	NULL
41	NULL
.	NULL

Koike	NULL
M	NULL
,	NULL
Ishino	NULL
K	NULL
,	NULL
Ikuta	NULL
T	NULL
,	NULL
Huh	NULL
N	NULL
,	NULL
Kuroki	NULL
T	NULL
:	NULL
Growth	NULL
enhancement	NULL
of	NULL
normal	NULL
human	NULL
keratinocytes	NULL
by	NULL
the	NULL
antisense	NULL
oligonucleotide	NULL
of	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
.	NULL

Oncogene	NULL
10:117	NULL
,	NULL
1995	NULL
2227	NULL
42	NULL
.	NULL

Hollenbaugh	NULL
D	NULL
,	NULL
Grosmaire	NULL
LS	NULL
,	NULL
Kullas	NULL
CD	NULL
,	NULL
Chalupny	NULL
NJ	NULL
,	NULL
Breasch-Anderson	NULL
S	NULL
,	NULL
Noelle	NULL
RJ	NULL
,	NULL
Stamenkovic	NULL
I	NULL
,	NULL
Ledbetter	NULL
JA	NULL
,	NULL
Aruffo	NULL
A	NULL
:	NULL
The	NULL
human	NULL
T	NULL
cell	NULL
antigen	NULL
gp39	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
TNF	NULL
gene	NULL
family	NULL
,	NULL
is	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
CD40	NULL
receptor	NULL
:	NULL
Expression	NULL
of	NULL
a	NULL
soluble	NULL
form	NULL
of	NULL
gp39	NULL
with	NULL
B	NULL
cell	NULL
costimulatory	NULL
activity	NULL
.	NULL

EMBO	NULL
IJ	NULL
11:4313	NULL
,	NULL
1992	NULL
43	NULL
.	NULL

Urashima	NULL
M	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Hatzianni	NULL
M	NULL
,	NULL
Ogata	NULL
A	NULL
,	NULL
Hollenbaugh	NULL
D	NULL
,	NULL
Aruffo	NULL
A	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
CD40	NULL
ligand	NULL
triggers	NULL
interleukin-6-mediated	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

Leuk	NULL
Res	NULL
(	NULL
in	NULL
press	NULL
)	NULL
44	NULL
.	NULL

Wang	NULL
JYJ	NULL
,	NULL
Knudsen	NULL
ES	NULL
,	NULL
Welch	NULL
PJ	NULL
:	NULL
The	NULL
retinoblastoma	NULL
tumor	NULL
suppressor	NULL
protein	NULL
.	NULL

Adv	NULL
Cancer	NULL
Res	NULL
64:25	NULL
,	NULL
1994	NULL
45	NULL
.	NULL

Ogata	NULL
A	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Urashima	NULL
M	NULL
,	NULL
Dedera	NULL
D	NULL
,	NULL
Hatziyanni	NULL
M	NULL
,	NULL
Vidriales	NULL
MB	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
Interleukin-6	NULL
triggers	NULL
multiple	NULL
myeloma	NULL
cell	NULL
growth	NULL
via	NULL
the	NULL
Ras	NULL
dependent	NULL
mitogen	NULL
activated	NULL
protein	NULL
kinase	NULL
cascade	NULL
.	NULL

(	NULL
submitted	NULL
)	NULL
46	NULL
.	NULL

Tricot	NULL
G	NULL
,	NULL
Barlogie	NULL
B	NULL
,	NULL
Jagannath	NULL
S	NULL
,	NULL
Bracy	NULL
D	NULL
,	NULL
Mattox	NULL
S	NULL
,	NULL
Vesole	NULL
DH	NULL
,	NULL
Naucke	NULL
S	NULL
,	NULL
Sawyer	NULL
JR	NULL
:	NULL
Poor	NULL
prognosis	NULL
in	NULL
multiple	NULL
myeloma	NULL
is	NULL
associated	NULL
only	NULL
with	NULL
partial	NULL
or	NULL
complete	NULL
deletions	NULL
of	NULL
chromosome	NULL
13	NULL
or	NULL
abnormalities	NULL
involving	NULL
11q	NULL
and	NULL
not	NULL
with	NULL
other	NULL
karyotype	NULL
abnormalities	NULL
.	NULL

Blood	NULL
86:4250	NULL
,	NULL
1995	NULL
47	NULL
.	NULL

DeBoer	NULL
CJ	NULL
,	NULL
Schuuring	NULL
E	NULL
,	NULL
Dreef	NULL
E	NULL
,	NULL
Peters	NULL
G	NULL
,	NULL
Bartek	NULL
J	NULL
,	NULL
Kluin	NULL
PM	NULL
,	NULL
vanKrieken	NULL
JHJM	NULL
:	NULL
Cyclin	NULL
D1	NULL
protein	NULL
analysis	NULL
in	NULL
the	NULL
diagnosis	NULL
of	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
.	NULL

Blood	NULL
8§6:2715	NULL
,	NULL
1995	NULL
48	NULL
.	NULL

Hirama	NULL
T	NULL
,	NULL
Koeffier	NULL
PH	NULL
:	NULL
Role	NULL
of	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitors	NULL
in	NULL
the	NULL
development	NULL
of	NULL
cancer	NULL
.	NULL

Blood	NULL
86:841	NULL
,	NULL
1995	NULL
49	NULL
.	NULL

Chellappan	NULL
SP	NULL
,	NULL
Hiebert	NULL
S	NULL
,	NULL
Mudryj	NULL
;	NULL
M	NULL
,	NULL
Horowitz	NULL
JM	NULL
,	NULL
Nevins	NULL
JR	NULL
:	NULL
The	NULL
E2F	NULL
transcription	NULL
factor	NULL
is	NULL
a	NULL
cellular	NULL
target	NULL
for	NULL
the	NULL
RB	NULL
protein	NULL
.	NULL

Cell	NULL
65:1053	NULL
,	NULL
1991	NULL
50	NULL
.	NULL

Chen-Kiang	NULL
S	NULL
,	NULL
Hsu	NULL
W	NULL
,	NULL
Natkunam	NULL
Y	NULL
,	NULL
Zhang	NULL
X	NULL
:	NULL
Nuclear	NULL
signaling	NULL
by	NULL
interleukin-6	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
5:124	NULL
,	NULL
1993	NULL
51	NULL
.	NULL

Santhanam	NULL
U	NULL
,	NULL
Ray	NULL
A	NULL
,	NULL
Sehgal	NULL
P	NULL
:	NULL
Repression	NULL
of	NULL
interleukin	NULL
6	NULL
gene	NULL
promotor	NULL
by	NULL
p53	NULL
and	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
USA	NULL
88:7605	NULL
,	NULL
1991	NULL
52	NULL
.	NULL

Robbins	NULL
PD	NULL
,	NULL
Horowitz	NULL
JM	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Negative	NULL
regulation	NULL
of	NULL
human	NULL
c-fos	NULL
expression	NULL
by	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
346:668	NULL
,	NULL
1990	NULL
53	NULL
.	NULL

Ray	NULL
A	NULL
,	NULL
LaForge	NULL
K	NULL
,	NULL
Sehgal	NULL
PB	NULL
:	NULL
On	NULL
the	NULL
mechanism	NULL
for	NULL
efficient	NULL
repression	NULL
of	NULL
the	NULL
interleukin-6	NULL
promoter	NULL
by	NULL
glucocorticoids	NULL
:	NULL
en-hancer	NULL
,	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
RNA	NULL
start	NULL
site	NULL
(	NULL
Inf	NULL
Motif	NULL
)	NULL
occlusion	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
10:5736	NULL
,	NULL
1990	NULL
54	NULL
.	NULL

Adnanet	NULL
J	NULL
,	NULL
Shao	NULL
ZZ	NULL
,	NULL
Robbins	NULL
PD	NULL
:	NULL
The	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
represses	NULL
transcription	NULL
when	NULL
directly	NULL
bound	NULL
to	NULL
the	NULL
promotor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:8837	NULL
,	NULL
1995	NULL
55	NULL
.	NULL

MacLead	NULL
SL	NULL
,	NULL
Bellido	NULL
TM	NULL
,	NULL
Epstein	NULL
J	NULL
,	NULL
Manolagas	NULL
SC	NULL
,	NULL
Barlogie	NULL
B	NULL
,	NULL
Hardin	NULL
JW	NULL
:	NULL
Transcription	NULL
factor	NULL
binding	NULL
to	NULL
IL-6	NULL
promotor	NULL
correlates	NULL
with	NULL
IL-6	NULL
production	NULL
by	NULL
6	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
Am	NULL
Ass	NULL
Canc	NULL
Res	NULL
36:3187a	NULL
,	NULL
1995	NULL
(	NULL
abstr	NULL
)	NULL
56	NULL
.	NULL

Urashima	NULL
M	NULL
,	NULL
Chauhan	NULL
D	NULL
,	NULL
Uchiyama	NULL
H	NULL
,	NULL
Freeman	NULL
GJ	NULL
,	NULL
Anderson	NULL
KC	NULL
:	NULL
CD40	NULL
ligand	NULL
triggers	NULL
interleukin-6	NULL
secretion	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

Blood	NULL
85:1903	NULL
,	NULL
1995	NULL
57	NULL
.	NULL

Zhu	NULL
Y-M	NULL
,	NULL
Bradbury	NULL
D	NULL
,	NULL
Russell	NULL
N	NULL
:	NULL
Decreased	NULL
retinoblastoma	NULL
protein	NULL
expression	NULL
in	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
autologous	NULL
proliferation	NULL
of	NULL
clonogenic	NULL
blasts	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
86:533	NULL
,	NULL
1994	NULL
58	NULL
.	NULL

Zhu	NULL
Y-M	NULL
,	NULL
Bradbury	NULL
DA	NULL
,	NULL
Keith	NULL
FJ	NULL
,	NULL
Russell	NULL
N	NULL
:	NULL
Absence	NULL
of	NULL
retinoblastoma	NULL
protein	NULL
expression	NULL
results	NULL
in	NULL
autocrine	NULL
production	NULL
of	NULL
interleukin-6	NULL
and	NULL
promotes	NULL
the	NULL
autonomous	NULL
growth	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
blast	NULL
cells	NULL
.	NULL

Leukemia	NULL
8:1982	NULL
,	NULL
1994	NULL
59	NULL
.	NULL

Weide	NULL
R	NULL
,	NULL
Tiemann	NULL
M	NULL
,	NULL
Pfluger	NULL
K-H	NULL
,	NULL
Koppler	NULL
H	NULL
,	NULL
Parvizl	NULL
B	NULL
,	NULL
Wacker	NULL
H-H	NULL
,	NULL
Kreipe	NULL
H-H	NULL
,	NULL
Havemann	NULL
K	NULL
,	NULL
Parwaresch	NULL
MR	NULL
:	NULL
Altered	NULL
expression	NULL
of	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
in	NULL
human	NULL
high	NULL
grade	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
.	NULL

Leukemia	NULL
8:97	NULL
,	NULL
1994	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1996	NULL
88	NULL
:	NULL
2219-2227	NULL
Interleukin-6	NULL
promotes	NULL
multiple	NULL
myeloma	NULL
cell	NULL
growth	NULL
via	NULL
phosphorylation	NULL
of	NULL
retinoblastoma	NULL
protein	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
M	NULL
Urashima	NULL
,	NULL
A	NULL
Ogata	NULL
,	NULL
D	NULL
Chauhan	NULL
,	NULL
MB	NULL
Vidriales	NULL
,	NULL
G	NULL
Teoh	NULL
,	NULL
Y	NULL
Hoshi	NULL
,	NULL
RL	NULL
Schlossman	NULL
,	NULL
JA	NULL
DeCaprio	NULL
and	NULL
KC	NULL
Anderson	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/88/6/2219.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

